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New Zealand peritoneal dialysis survey. J.F. Collins, G. Gamble, J.
Leary, Department of Medicine, Auckland Hospital, New Zealand.
This prospective survey includes all New Zealand patients on CAPD
since 1986. Its intent was to provide baseline data on hypertension,
smoking, and non-renal disease with detailed information about out-
comes including peritonitis, hospitalization. CAPD termination and
specified major non-renal illnesses. A breakdown was provided by
center, ethnic origin, age and the presence or not of diabetes mellitus.
An initial baseline record was completed on each patient with event
reports 3 times monthly and reports of each peritonitis episode. From
1/11/86 to 1/11/90 441 patients have been commenced on CAPD. A
further 174 patients who commenced CAPD therapy prior to Ill 1/86
were maintained on CAPD after 1/I 1/86 and are included in some of the
analyses. Of new patients commenced after 1/11/86, 54% were Europe-
ans, 33% Maori and 10% Pacific Islanders. A total of 53% Maori and
40% of Pacific Islanders had diabetes mellitus compared with 17% of
Europeans; 71% of Maori and Polynesian diabetics were NIDDM vs.
13% of European diabetics; and 66% of new patients had a history of
smoking cigarettes at some past time, though only 22% were smoking in
the 3 months prior to dialysis. Using M-H x2 analysis patients with a
smoking history had a significantly higher mortality rate than non-
smokers (P < 0.024). Vascular risk was quantitated using a scoring
system for the presence of ischemic heart disease, cerebrovascular
disease and peripheral vascular disease. In those patients judged to
have a significant vascular risk score (21%) the mortality rate was
significantly increased. (M-H g P < 0.001) The average hospital days
per patient year in 1989 were 22.5 with 11.1 days ascribed to CAPD-
related illness. The average peritonitis incidence in 1989 was I episode!
8.4 patient-months. In conclusion, the NZ CAPD survey provides
comprehensive data about risk factors and outcomes in this group of
patients.
Prospective randomized study of peritonitis with conventional versus
0-set techniques in CAPD. J. Owen, R. Walker, G. Becker, Department
of Nephrology, Royal Melbourne Hospital, Victoria 3050. Australia.
We performed a prospective randomized trial, comparing the incidence
of peritonitis between a flush-disconnect (0-system, Baxter) (OS) and a
conventional (System 11, Baxter) (CS) continuous ambulatory perito-
neal dialysis (CAPD) method. Sixty consenting patients with no severe
physical impairment commencing CAPD between May 1987—May 1989
were entered and followed to May 1990. There were 30 OS and 30 CS
patients. Age, gender and time for training did not differ significantly.
There were 2 diabetics in OS, 6 in CS (P = NS). The period of
observation was 375 months for OS and 430 months for CS. OS
experienced 28 episodes of peritonitis (15.4 months/pt/episode) com-
pared with 88 (5.2 months/pt/episode) in CS (P < 0.005). By 6 months
32% of OS had at least one episode of peritonitis, compared with 62%
of CS; at 18 months the figures were 52% for OS and 90% for CS (P <
0.01), (Life Table Analysis). The median survival time to first peritonitis
was 5.1 in CS, 9.7 in OS (P < 0.01). The cost of OS (excluding
peritonitis treatment) was $18,312 compared with $12,428 for CS. While
the use of the OS substantially reduced the costs of treating peritonitis
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in our hospital from approximately $2,060/pt/year in the CS group to
$800/pt/year in the OS group, this was not sufficient to offset the
substantially increased cost of the OS.
Long-term effects of hepatitis B virus infection on recipients of living
related donor (LRD) renal allografts. PP. Thomas, C.K. Jacob, and
J.C.M. Shastry, Department of Nephrology, Christian Medical College
Hospital, Vellore, India. The long-term patient and graft survival of
LRD renal transplant recipients with and without hepatitis B virus
infection were studied. Between 1971 and 1983, 288 patients received
306 LRD renal allografts. A total of 176 were HB5Ag negative (Group
1) and 79 were HBsAg positive. Hepatitis developed in 19% of HBsAg
positive patients compared to 4% of Group I (P < 0.01). Eighteen
percent of the deaths were due to hepatocellular failure in those positive
for HBsAg compared to 1.5% of the deaths in Group 1(P <0.05). Of the
HBsAg +ve patients, 33 acquired the infection in the post-transplant
(Group II) and 26 were positive through dialysis and post-transplant
periods (Group 111). The graft survival of the patients of Group I, II and
Ill were 45.2%, 56.4% and 37.7%, respectively, at 5 years (P < 0.05).
At 10 years it was 39.2%. 50.4%. and 23.9%, respectively, in the three
groups (Group II vs. Group III, P < 0.01). Thus patients with hepatitis
B infection had significantly higher incidence of hepatitis and hepato-
cellular failure compared to those without the infection. Those who
acquired the infection in the dialysis period or before had poorer patient
and graft survival at 10 and 15 years compared to those who acquired
the infection in the post-transplant period.
Pregnancy after renal transplantation—Outcome and effect on renal
function. JR. Burke, I.R. Hard/c, B. Menzies, J.J. Petrie, R. Righy, C.
Hawley, P. Boyle, Princess Alexandra ana Mater Mothers Hospitals,
Brisbane, Queensland, 4102, Australia. Pregnancies in renal allograft
recipients are potentially hazardous because of risks for graft function
and perinatal complications. Between 1968 and 1989, 29 pregnancies
were recorded in 22 women who had renal transplants in Queensland.
Surgical abortion was performed in 8 and spontaneous abortion oc-
curred in 2. Eighteen pregnancies ended with normal children, including
2 sets of twins. There was 1 intrauterine death (35 wk), and two patients
are currently pregnant. In the 18 pregnancies extending beyond 26
weeks, immunosuppression was prednisolone and azathioprine in 17
and cyclosporine in 1. Mean interval from transplant to pregnancy was
4.3 years (range 4 months—I year). Complications during pregnancy
included hypertension (8), threatened abortion (I), UTI (I), PET (5) and
prematurity (5). There were no complications in 3. Mode of delivery
was caesarean section in 16 and vaginal in 2. Perinatal complications
were RDS (6), growth retardation (2), and hypoglycemia (I). There
were no neonatal deaths or congenital malformations. School perfor-
mances in 10 of the II school-aged children is satisfactory; 1 has mild
learning difficulties. In 17 pregnancies in which serum creatinine was
<ISO zmol!liter there was no change in renal function from start of
pregnancy to time of delivery and in the 12 months postpartum.
Start Term One year
Serum creatinine 102.6 20,4 102.6 21.7 101.5 17.6
jzmol/liter (mean NS NS
SD)
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Initial serum creatinine <150 mol/Iiter and good BP control predicted
successful pregnancy outcome. There was no adverse effect on renal
function and no congenital abnormalities. The children have developed
normally.
Cyclosporine (CsA)-induced chronic renal injury despite normalization
of renal function with drug withdrawal. W.M. Bennett, L. Elzinga,
Oregon Health Sciences University, Portland, Oregon, USA. Previous
studies have shown a correlation between CsA induced experimental
renal failure and medullary ray and inner stripe injury (Transplantation
49:445, 1990). Clinically, normalization of GFR after drug withdrawal or
dosage reduction is used as evidence that acute nephrotoxicity (NTx)
has resolved. To ascertain the natural history of this lesion when CsA
is withdrawn, we studied the relationship between renal functional
impairment and structural changes in groups of uninephrectomized rats
treated with CsA 15 mg/kg/day s.c., or vehicle (Veh), plus a low salt diet
for 28 days (CsA 28). GFR and morphology were assessed (blinded) 14
and 28 days after drug withdrawal (N = 5 to 7/group). Mean s.
CIN (mi/min/I00 g)
Chronicity In
Cortex
1.7 0.2
dcx (0-4+)
Medulla
1.9 0.3CsA 28 0.06 0.02
CsA 28 + 14d 0.17 0.02 2.1 0.3 2.6 0.3
CsA 28 + 28d 0.32 0. l3 2.0 0.3 2.3 0.4
Veh (all times) 0.48 0.50 0.06" <0,19h
a P < 0.001 from nadir; b P < 0.01 from CsA
Renal injury included medullary ray fibrosis and atrophy and extensive
mTAL atrophy. CsA treated rats on high salt diet had similar acute NTx
(CIN 0.09 0.04) but minimal chronic injury (0.5). Conclusion:
Reversal of renal hemodynamic changes with improvement of GFR on
withdrawal of CsA cannot be used to exclude chronic CsA NTx.
Sodium intake is an important determinant of Cl, but not the acute
Nix, associated with CsA.
Experimental model of the microangiopathic form of cyclosporin A
toxicity. P. Faraco, T. Hewitson, P. Kincaid-Sinith, Department of
Nephrology, Royal Melbourne Hospital. Victoria, 3050, Australia. The
microangiopathic form of cyclosporin A (CsA) toxicity has been asso-
ciated with major immunologic insults. We studied the effects of
lipopolysaccharide (LPS) infusion on CsA-treated rabbits. Twenty
NZW rabbits were divided into four groups. The animals received CsA
or diluent for 10 days and were infused with LPS or saline on day 11 via
the marginal ear vein for 5 hours. After infusion they were sacrificed,
kidneys removed and processed for light and electron microscopy.
Group I received CsA diluent and saline. Group 11 received CsA and
saline. Group III received CsA diluent and LPS. Group IV received
CsA and LPS. No fibrin deposition was found in groups I and II. We
found 5.4% glonieruli with fibrin in group Ill and 84.8% glomeruli with
fibrin deposits in group IV (P < 0.001). No glomerular thrombi were
observed in group Ill, but in group IV 38% of glomeruli contained
thrombi. The lesions in the group treated with CsA and infused with
LPS strongly resembled those which develop in the microangiopathic
form of CsA toxicity in the human kidney.
Pathobiology of subclinical pyelonephritis—An experimental evalua-
tion. T.E. Miller, G. Findon, Department of Medicine, Auckland
Hospital, Auckland, New Zealand. Clinical studies have shown that, in
proven cases of significant bacteriuria, 30—60% of the infections can be
localized to the upper urinary tract. Data from the same case studies
have also documented a poor correlation between symptoms of upper
urinary tract infection and results of localization tests, leading to the
conclusion that factors other than bacterial invasion of the kidney per se
determine clinical symptoms. One explanation for a symptomless
bacterial invasion of the kidney could be that the site is colonized.
rather than infected, and the microorganisms establish a subclinical
presence which fails to induce an inflammatory response and an
associated lesion. There is a need to show that such a situation can
actually occur and, in the present experiment, we set out to character-
ize an animal model of renal microbial invasion which promised to
mimic the postulated features of subclinical renal infection in humans.
The model has been used to obtain quantitative information on the
comparative pathobiology of a subclinical and a classic lesion-inducing
infection and to define the host-parasite interaction that allows micro-
organisms to persist in the kidney without stimulating a host response.
These observations may explain the absence of symptoms in clinical
cases of urinary tract infection where a host-parasite relationship,
equivalent to the situation in the animal model, is present. We suggest
that symptoms arise when microbial invasion of renal tissue leads to the
establishment of infection (not colonization), an event which is associ-
ated with an inflammatory reponse and local lesion formation.
Genotypic and phenotypic expression of the Goodpasture antigen in
canine hereditary nephritis. D. Chew, J. Savige, J. Hood, M. French,
M. Thomas, W. Robinson, School of Veterinary Studies, Murdoch
University of WA, Departments of Nephrology andimmunology, Royal
Perth Hospital WA, Department of Haematology, Repatriation Hospi-
tal, Heidelbe,'g, Victoria, Australia. A canine model of inherited renal
disease, proteinuria, progressive uremia, and hematuria has been
described in WA. bull terriers. The glomerular basement membrane
(GBM) abnormality is ultrastructurally similar to human Alport's syn-
drome; the inheritance is autosomal dominant. To determine whether
the lack of renal immunoreactivity of Goodpasture antigen described in
human Alport's is shared by the canine model, 2 high titer anti-human
GBM antibody sera showing cross-reactive linear GBM immunofluo-
rescence on normal non-bull terrier canine kidney were studied on a
non-proteinuric, a proteinuric non-uremic and a proteinuric uremic
non-end-stage bull terrier kidney. Non-proteinuric bull terrier kidney
had normal linear GBM reactivity; proteinuric bull terriers had absent
GBM reactivity whether uremic or nonuremic. eDNA from bull terrier
kidney mRNA (3 affected and 2 unaffected dogs) was amplified by
polymerase chain reaction, demonstrating in all samples the presence of
mRNA corresponding to the putative 000dpasture antigen (the non-
collagenase domain of the alpha 3 chain of type IV collagen), without
the corresponding region of the alpha 4 chain. WA bull terrier nephrop-
athy is associated with phenotypic suppression but not deletion of the
putative Goodpasture antigen gene—the defect is postulated to be a
post-translational modification.
Extracellular matrix accumulation in purine aminonucleoside nephro-
sis. C. Jones, S. Bach, M. Post, A. Eddy, The Hospital for Sick
Children, University of loronto, Toronto, Ontario, Canada. The mo-
lecular processes involved in the accumulation of extraceilular matrix
(ECM) in the 2-kidney single dose model of purine aminonucleoside
(PAN) ncphrosis were investigated. Female Lewis rats were injected up
with PAN 15 mg/l00 g body weight (N = 60) or saline (N = 50) in 4
experiments. Atbuminuria was measured weekly. Renal tissue was
collected at times 0.5. 1,2,6 and 24 hours; 4 days; I, 2 and 3 weeks. The
intrarenal steady state mRNA concentrations of ECM proteins, the
metalloproteinases that degrade the ECM (interstitial collagenase and
stromelysin), the tissue inhibitor of the metalloproteinases (TIMP), and
a marker of cellular proliferation, histone, were measured by Northern
blotting. The deposition of ECM proteins and TIMP were assessed
semiquantitatively by fluorescence microscopy of frozen kidney sec-
tions. The site of production of collagen alpha-l(I) was investigated by
RNA in situ hybridization. By 3 weeks, the IF studies revealed
increased tubulointerstitial and glomerular accumulation of collagen IV,
laminin, fibronectin and T1MP while expression of collagens I and III
increased in the tubulointerstitium. The relative increase of each matrix
protein was greater in the interstitium than in glomeruli. The results of
Northern blotting for collagen IV (alpha-I and alpha-2) and laminins B1
and B, were similar. Concentrations of mRNA were decreased com-
pared to controls for the first 4 days but increased to 1,000% of control
values at I week and then decreased to 300% of control values by 3
weeks. Concentrations of mRNA for TIMP and fibronectin were
increased by 300% at I week and decreased to control values at 3
weeks. Interstitial collagenase mRNA concentrations were slightly
increased at I and 2 weeks and those for stronielysin were unchanged.
Flistone mRNA concentrations were suppressed over the first day of
injury but increased to 125% and 1,000% of control values by 4 days and
I week, respectively, before decreasing to 125% of controls at 2 and 3
weeks. Radiolabelled thymidine incorporation revealed the cellular
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proliferation involved tubular epithelial and interstitial cells. In conclu-
sion, the accumulation of ECM proteins in this model appears to be due
to both an increase in intrarenal matrix gene transcription and reduced
matrix degradation caused by an upregulation of TIMP production.
These processes are most active at I week when nephrotic syndrome
and renal cell proliferation are maximal.
Effect of bicarbonate administration on skeletal muscle intracellular pH
in the rat. C.H. Thompson, PD. Syme, M.E. Williams, J.G. Leding-
ham, G.K. Radda, MRC Biochemical and Clinical Magnetic Reso-
nance Unit, John Radcliffe Hospital, Headington, Oxford, 0X3 9DU,
UnitedKingdom. Bicarbonate (HCO3) is used in the management of life
threatening acidosis. However, there is evidence in vitro that sudden
extracellular addition of HCO3 results in intracellular acidification due
to carbonic anhydrase activity. The aim of this study was to determine
whether sudden HCO3 administration results in intracellular acidosis in
vivo. We measured changes in rat skeletal muscle cytosolic pH (pHi)
using 3Ip nuclear magnetic resonance spectroscopy (NMR) in 15 intact
male 13-week-old Wistar-Kyoto (WKY) rats, mean BP 120 (SD 10) mm
Hg. All experiments were performed using halothane/N,O/02 anesthe-
sia. A group of 5 rats were given 0%, 6%, 14% and 20% inhaled carbon
dioxide (C02) concentrations and intrinsic buffering determined from
the calculated change in intracellular HCOI for a given change in pHi as
measured by NMR. Under 0% inhaled CO2. another group of 5 rats
were given 10 mEq/kg of sodium bicarbonate intraperitoneally (i.p.).
and a further group of 5 rats acted as controls and were given 10 mEq/kg
sodium chloride i.p. NMR measurements of pHi were made at rest and
up to 15 minutes after i.p. injections. Intrinsic buffering in rat skeletal
muscle in vivo was calculated to be 47.6 mmol/liter/pH unit. HCO3
administration resulted in a decrease in skeletal muscle pHi from 7.06
(so 0.02; N = 5) to 7.00 (so 0.01; N = 5) within 5 minutes (P < 0.01),
corresponding to a hydrogen ion load to the skeletal muscle of 2.9
mmol/liter. Respiratory rate increased with intracellular acidosis.
Venous P0, increased but arterial P0, remained constant after HCO3.
We conclude that acute administrati6n of HCO3 produces an initial
intracellular acidosis in vivo. This has important implications regarding
the use of HCO3 therapy to correct acidosis in man.
Combined hepatic and renal transplantation for primary oxalosis in
three patients. A. Hennessy. J.F. Thompson, J. Horvath, G. Mc-
Caughan, L.P. Roy, A.G.R. Sheil, Di. Tiller, Royal Prince Alfred
Hospital, Camperdown, Sydney, NSW, 2050, Australia. Two adults
and one child with primary oxaluria type I (PHI) have been successfully
treated with combined liver and kidney transplantation. All three
patients had primary oxaluria type I with a liver biopsy-proven defi-
ciency of alanine:glyoxylate aminotransferase (AGT). The family his-
tories of these patients show one family with multiple deaths of siblings
under one year of age. The outcome of molecular genetic studies in one
family show the index case to be homozygous for three amino acid
substitutions which are 100% linked to AGT mistargeting in PHI. These
three mutations occur in one third of patients with PHI. The parents
and one brother were carriers. heterozygous for all three mutations.
The patients were blood group compatible but HLA mismatched
(except for HLA A identity in one of the patients). Complications
included hepatic and renal rejection in two out of the three patients. The
child developed hepatic failure due to hepatic artery thrombosis and
renal graft rejection so a second combined procedure was successfully
performed. Further hepatic rejection was treated with OKT3. Three
patients are alive and well 24, 12 and 4 months after transplantation.
They have normal hepatic function. All patients have a creatinine under
ISO gm/liter. They remain on combined immunosuppression, cyclospo-
rine, prednisone and azathioprine. Cardiac, muscle, neurological and
renal failure complications of their primary oxalosis improved, suggest-
ing that combined transplantation is the treatment of choice in this
disease.
Renal transplant duplex scan, TcDTPA or biopsy? E. Fischer, V.
Antico, R.D.M. Allen, D. Er, J. Mackie, S. Grunnewald, 1). Farlow, S.
Lawrence, D.C.H. Harris, J.H. Stewart. JR. Chapman, Renal Unit,
Department of Medicine, Westmead Hospital, NSW, 2145, Australia.
The relative roles of renal allograft biopsy, doppler ultrasound mea-
surement of renal blood flow and TcDTPA scan in the diagnosis of renal
dysfunction have yet to be assessed. We have therefore assessed 44
renal transplant recipients by routine biopsy, ultrasound and DTPA
scan. RI (N = 301) was calculated from peak systole-trough diastole/
peak systole, and was measured within 24 hours of all renal allograft
biopsies and at times of renal dysfunction. Renal biopsy (N = 162) was
performed on days 7, 21, 90. 365 and when indicated for diagnosis of the
course of renal dysfunction. Biopsies were reviewed by a single
observer without knowledge of the ultrasound on clinical findings and
the results of 20 individual characteristics graded. DTPA scan was
performed on a mean of 3.9 times per patient. RI was significantly
influenced by time after transplantation and was raised when the biopsy
showed acute tubular necrosis (ATN), red cell extravasation, perivas-
cular lymphocyte infiltration, arterial wall cellular infiltration, or a
diffuse interstitial infiltrate with or without focal accentuation. Focal
infiltration of the graft, edema and arteriolar hyalinosis did not correlate
with the RI. A rise in Ri by more than 0.05 to a value of more than 0.85
was associated within 72 hours with a clinicopathiological diagnosis of
acute rejection on 15 of 23 occasions. However other causes of absent
of diastolic flow (RI = 1.0) were ureteric obstruction and vascular
occlusion. DTPA scan demonstrated renal blood flow and was more
sensitive than U/S for assessment of potential ureteric obstruction. We
conclude that a raised RI occurs in many situations including ATN, but
that it may be associated with histopatho][ogical change indicative of
acute rejection, while the major role of the DTPA scan was useful for
assessment of urinary obstruction.
Potential availability of donor organs from the intensive care units
(ICU's) of two major west Australian teaching hospitals. H. Rhodes,
PD. Cameron, E.F. Haywood, K. Y. Lee, B.M. Saker, Departments of
Nephrology and Intensive Care, Sir Charles Gairdner and Royal Perth
Hospitals, Perth, Australia. The proposed appointment of a local
transplant co-ordinator and the expansion of transplant services to
include tissues other than renal and corneal grafts were the indications
for this study. To estimate the likely annual availability and nature of
tissues, all patients who died in the ICU's of Sir Charles Gairdner and
Royal Perth Hospitals in 1989 were assessed retrospectively as to their
potential as donors of perfused (liver, kidney, heart, lungs) and non-
perfused (heart valves, corneas, bone) tissues. Of a total 245 deceased
patients, case notes were first viewed for the 101 patients under 60 years
of age. Donor tissue was harvested from 13 patients. In 8 suitable cases,
permission for organ donation was refused. Permission was not sought
in two instances because of likely refusal. Fifty-five cases were ex-
cluded due to sepsis, malignancy, systemic disease or toxic exposure;
17 patients with significant hemodynamic instability, were potential
donors of non-perfused tissues, including 2 corneal donors and 5
patients in whom inability to confirm brain death precluded the use of
perfused organs. Assessment of an additional 63 patients, aged 60—70
years revealed a high incidence of concurrent systemic disease, with
only 2 potential donors identified. This study has demonstrated the
limited number of potential organ donors irt W. Australia and confirmed
that the majority of them are at present being adequately identified.
Universal occurrence of renal abnormalities in patients receiving liver
transplants. S.f. Fleming, D.H.G. Crawford, R.A. Axelsen, S.V.
Lynch. GA. Balderson, R.W. Strong, P. Kerlin, LW. Powell, Z.H.
Endre, Departments of Renal Medicine, Royal Brisbane Hospital,
Her.ston, 4029, Medicine, University of Queensland; Pathology, Sur-
gery, Gastroenterology, Princess Alexandra Hospital, Queensland,
Australia. Glomerular abnormalities occur commonly in association
with cirrhosis of the liver, but their incidence and the effect of
orthotopic liver transplantation (OLT) on such lesions is unknown. We
conducted a prospective study of renal histology and function in twelve
consecutive non-alcoholic patients who underwent OLT. Despite well
preserved renal function (creatinine clearance 1.5—2.6 mI/see: 24-hr
urinary protein excretion <200 mg in II patients, 270 mg in I) all
patients had abnormal renal biopsies. Four patterns of glomerular injury
were identified: minor glomerular abnormalities (5 patients), hepatic
glomerulosclerosis (5), membranoproliferative glomerulonephritis (1)
and IgA nephropathy (I). Patients with minor glomerular abnormalities
had lower plasma bilirubin and higher plasma albumin than patients
with more severe forms of glomerular injury (23 vs. 82 mol/liter, P =
0.01; 38 vs. 28 g/liter, P = 0.05). 1gM immunofluorescence was present
in all biopsies and IgA in seven. 1gM containing circulating immune
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complexes occurred in three patients, suggesting a pathogenic role for
1gM immune complex deposition. The glomerular lesions persisted in
follow-up biopsies obtained from 6 patients a maximum of 3 months
post-OLT. The significance of cirrhosis associated glomerular abnor-
malities is not yet known. They may contribute to the hepatorenal
syndrome and the renal dysfunction which occurs in up to 94% of
patients post-OLT.
Prevalence of hepatitis C antibody in a dialysis unit. A .G. Stein, A .P.S.
Disney, Queen Elizabeth Hospital, SA 5011, Australia. To assess the
prevalence of hepatitis C antibody (HCV) in our dialysis unit, we used
the Ortho Immunoassay to test all chronic dialysis patients (pts) treated
during July 1990. There were 162 pts (17 CAPD, 145 HD) of whom 21
(13%) were 1-ICV positive (HCV+). One of two hepatitis B carrier pts
was HCV+. Among 29 Aboriginal pts, 2 (6.9%) were HCV+. These
HCV+ pts were compared to 21 I-ICy negative (HCV—) pts chosen
randomly as controls from the dialysis population. Duration of treat-
ment, units of blood transfused, record of abnormal liver function and
previous transplantation were assessed. HCV+ pts (mean age 51.6
years) had a median treatment period of 119 months (range 6—60
months); 14 (67%) had received more than 10 units of blood, IS had had
abnormal liver function, and 8 had had a previous transplant. HCV—
pts (mean age 49.5 years) had a median treatment period of 41 months
(range 1—197 months); II (52%) had received more than 10 units of
blood, 8 had had abnormal liver function, and 8 had had a previous
transplant. Abnormal liver function was defined as hepatic enzyme
(AST/ALT) levels greater than twice the upper limit of normal (45
U/liter) on at least two occasions more than a month apart. Only 3
HCV+ pta had persisting mild elevation of hepatic transaminase; one
with hepatic failure subsequently died from gram negative septicemia.
Autopsy showed hemosiderosis and micronodular cirrhosis. Further
histological examination of some of these pts will be presented. No
HCV— pt had persisting ALT elevation. We conclude that the period of
treatment may be a significant factor in determining the presence of
HCV+ antibody (P < 0.05). Confirmatory tests for HCV antibody will
be performed. The significance of an HCV+ result will depend on
long-term evaluation of enzyme and histological changes in relation to
hepatic function.
Aspirin reduces recurrent dialyzer fiber clotting and improves urea
clearance (Ku). K. North, C. Zui'ela, H. Moody, H. Rhodes, M.
Thomas, Department of Nephrology, Royal Perth Hospital, WA 600/,
Australia. The effect of low dose aspirin on dialyzer fiber clotting and
urea clearance was assessed in 10 patients, 5 with recurrent macro-
scopic dialyzer fiber clotting, despite maximum tolerated blood flow
rates and heparin, and 5 without recurrent dialyzer fiber clotting.
Aspirin 75—100 mg, was given 30 minutes pre-hemodialysis (HD), for at
least I week. Ku (mi/mm) was measured pre- and post-HD, prior to and
after 1 week of aspirin therapy. Dialyzer fiber appearance was assessed
visually and recorded after each dialysis. There was no significant
difference between the patient groups with respect to dialyzer type
(plate or hollow fiber), vascular access (graft or fistula), blood flow rate
or hemoglobin. In the group as a whole, Ku fell from 182 15 pre-HD
to 172 15 post-HD (mean SD. P = 0.001, paired t-test) off aspirin.
By contrast, there was no significant fall in Ku with HD on aspirin.
Three of 5 patients with recurrent clotting had marked improvement in
macroscopic dialyzer fiber appearance on aspirin. On subgroup analy-
sis, the changes in Ku off- and on-aspirin were present in both clotters
and non-clotters, but did not reach statistical significance in the clotters
because of a small sample size. Low dose aspirin therapy given pre-HD
will reduce macroscopic dialyzer fiber clotting in some patients and
improve post-HD urea clearance in the majority of patients.
Nutritional assessment of children with renal failure receiving recom-
binant human growth hormone (rHuGH). J.F. Knight, B. Moore, BA.
Crawford, L. Baur, E. Reid, B. Allen, R.H. Howman-Giles, R. Widmer,
EM. Hodson, C. Cowell, K. Gaskin, M. Silink, L.P. Roy, The
Children's Hospital, Camperdown, NSW, Australia. Children with
renal failure often grow poorly, and are also often malnourished.
rHuGH may offer improved growth, but it is unclear how this treatment
affects, or is affected by, nutritional status. This study was undertaken
to examine the relationship between response to rHuGH therapy and
nutrition. Twenty-three children with growth failure due to chronic
renal failure (CRF) were given rHuGH (Genotropin, Kabi Pharmacia) I
U/kg/week for a year. Ten were on dialysis, 6 had functioning allografts,
7 had CRF only (GFR <30 ml/min/l.73 m2). Nutritional parameters
measured at 0, 6 and 12 months included standardized auxology, 5-day
weighed dietary records (0 & 6 months), lean body mass (LBM, by both
skinfold thickness and dual excitation x-ray absorptiometry) and total
body nitrogen (TBN, by neutron activation). This paper reports interim
results at 6 months. Mean height standard deviation score (SDS)
increased from —3.3 to —3.15 (P < 0.01). Annualized mean height
velocity increased from 3.6 to 7.1 cm/year (P < 0.001). Mean height
velocity SDS for bone age increased from —6.5 to 0.89 (P < 0.0025).
Growth response was heterogeneous, varying from 0 to 6 cm over 6
months. Four children did not grow at all. Energy intake was poor at
entry (mean 73%, range 30—118% of requirements for height age) and
did not improve significantly at 6 months. Protein intake exceeded
requirements at entry and at 6 months. LBM for height was significantly
greater that of a group of 69 healthy children. This observation was
attributed to edema. TBN for height was significantly less than that of
a group of 31 healthy children. This interim analysis confirms the
observation that rHuGH can improve growth velocity in children with
CRF. It also demonstrates that some of our patients have significant
nutritional impairment. At this interim analysis, response to rHuGH
and nutritional status did not appear to be consistently related.
Effect of dialyzer membrane reuse on serum beta2-niicroglobulin
concentration in haemodialysis patients. J. Westhuyzen, K. Foreman, D.
Saltissi, S. Fleming, Departments of Pathology and Renal Medicine,
Royal Brisbane Hospital. Hers/on, Queensland, 4029, Australia. Ele-
vated serum f32-microglobulin (/3,m) levels in long-term hemodialysis
patients have been associated with dialysis-related amyloidosis. Dialy-
sis membranes which remove f3m are expensive compared to standard
cuprammonium rayon. Dialyzer reuse reduces Costs, but there is little
information on the capacity of reprocessed dialyzers to remove /3,m.
We compared four dialyzer membranes on first, second and fourth use
of the dialyzer. Dialyzers were automatically reprocessed using the
peracetic acid-based sterilant, Renalin. Serum /32m levels were mea-
sured before and after dialysis in groups of 6 chronic hemodialysis
patients. Mean serum f32m (corrected for changes in plasma volume)
increased (by 16.3%) during dialysis with new cuprammonium rayon
(CUP) dialyzers (TAF 08, Terumo, 0.8 m2) but not with reprocessed
membranes. Dialysis with cellulose acetate (CA; Duo Flux, CD Medi-
cal, 1.5 m2) polyacrylonitrile (PAN; Filtral 10, 1.6 m2), or polymethyl-
methacrylate (PMMA; BK-I .6U, Toray, 1.6 m2) membranes resulted in
significant decreases in serum f32m levels (11.7, 27.7, and 46.6%,
respectively). Reuse reduced the effectiveness of PAN and PMMA
membranes, but they were still more effective on fourth use than new
CA membranes (reductions in serum f32m of 19.9 and 18.4%, respec-
tively). Our studies indicate that CUP is ineffective in removing /32m
from the circulation. CA membranes remove f32m by filtration and this
property is unaffected by reprocessing. PAN and PMMA membranes
remove J32m by both adsorption and filtration. Reprocessing does not
remove adsorbed $2m, thus the efficiency of PAN and PMMA declines
with successive reuse.
Twenty.six patient-years experience of hemofiltration using on-line
generation of sterile infusate. J. Petrie, R. Lenaghan, V. Wilson, Y.
Campbell, Renal Unit, Princess Alexandra Hospital, Brisbane, Q 4102,
Australia. The Gambro MPS machine, which produces sterile hemofil-
tration fluid on-line, has been used on 3947 occasions for a total
experience of 26.31 patient years. Twenty-nine patients were treated,
14 of whom had been on hemofiltration for over 12 months. The
indications were cardiovascular instability in 23, dialysis amyloidosis in
2, and the facilitation of full time employment in 4. No episodes of
bacteremia occurred in the 3947 treatments; there was one pyrogenic
reaction. Cardiovascular stability improved, and there was reduction in
post-dialysis fatigue. In the two patients with beta2-microglobulin
induced amyloidosis, there was considerable improvement in joint pain
and joint stiffness over a three month period. Two patients died, 7 were
successfully transplanted, 2 were transferred to other forms of dialysis
and 18 remain on hemofiltration. Actuarial patient survival was 91.9%
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at 6 months and 91.9% at one year. The effect of haemofiltration using
the Filtral 16 hemolilter on beta2-microglobulin is summarized below.
Number
Beta,-m mean
(mg/liter) SD
1. Hemofiltration pre-HF 14 32.2 4.81
2. post-HF 14 15.3 4.02
3. Dialysis pre-dialysis 51 44.82 11.85
4. post-dialysis 51 4L__ 12.34
I vs. 2, 1 vs. 3, and 2 vs. 4, P <0.001. 3 vs. 4, NS
Despite on line production of infusate and re-use of haemofilters,
haemofiltration remains some $20 per treatment more expensive than
conventional haemodialysis. This cost of disposables is balanced by a
reduction in treatment duration and in treatment induced morbidity.
Renal artery stenoses (RAS) in resistant hypertension (RHT). R.S.
Nanra, R.L. Martin, J. Wlodarczyk, A. DeSilva, A.E. Bray, Depart-
ments of Nephrology, Radiology and Clinical Epidemiology and Bio-
statistics, Royal Newcastle Hospital, and Cardiovascular Diagnostic
Centre, Newcastle, NSW, Australia. The incidence of RAS was inves-
tigated by renal angiography in patients with RHT defined as BP
>150/90mm Hg on at least 3 antihypertensive drugs. The findings in 55
analgesic nephropathy (AN) and 93 non-AN patients were:
AN Non-AN
Age years 30—79 40—79
Fibromuscular RAS 2 (4%) 3 (3%)
Atheromatous RAS 35 (64%) 37 (40%)
Bilateral RAS 8 (15%) 17 (18%)
Unilateral RAS 29 (53%) 23(24%)
RA thrombosis 9(16%) 6 (7%)
a p < 0.005
In 62 patients (115 renal arteries), renal hilar duplex scanning correctly
identified 45 of 52 RAS (>50% stenosis) and RA thrombosis, giving a
sensitivity of 87% and specificity of 98%. Post-captopril DTPA isotope
scans in 80 arteries demonstrated a sensitivity of 44% and specificity of
81% in detecting RAS. Follow-up renal hilar duplex scans in 8 patients
with successful angioplasty revealed normalized values. Conclusions:
(I) The incidence of RAS in RHT is high. (2) there is higher incidence
of atheroniatous RAS in AN patients, and (3) renal hilar duplex
scanning should be the initial method for screening for RAS.
Treatable complications in undiagnosed cases of autosomal-dominant
polycystic kidney disease. D. Ravine, R.G. Walker, R.N. Gibson, L.J.
Sheffield, P. Kincaid-Smith, D.M. Dank,c, Murdoch Institute, Royal
Children's Hospital, Parkville, Victoria 3052, Department of Nephrol-
ogy, Royal Melbourne Hospital, Department of Radiology, University
of Melbourne, Royal Melbourne Hospital, Australia. Three hundred
and twenty-one individuals born with a I in 2 risk of ADPKD, aged IS
years or older and not previously diagnosed as having the condition,
were assessed to determine the prevalence of undiagnosed cases of
autosomal-dominant polycystic kidney disease (ADPKD) as well as the
prevalence of untreatable complications in this undiagnosed group.
Sixty-eight (2 1%) had ultrasound evidence of polycystic kidney disease.
Of this previously undiagnosed group, 25 (37%) had one or more
significant complications at the time of diagnosis. The complications
included 20 cases of hypertension (diastolic blood pressure 95 mm
Hg), 7 cases of significantly impaired renal function (serum creatinine
0.12 mmol/liter) and 4 cases of bacterial urinary tract infection.
Overlapping complications were evident in 8 people. Hypertension and
raised serum creatinine levels were seen in 6 individuals. One person
had urinary infection as well as being hypertensive. Another individual
was hypertensive with an elevated serum creatinine as well as having
urinary infection. ADPKD has an important treatable component which
is not being addressed in a substantial proportion of affected individuals
because they are remaining undiagnosed despite the presence of a
known family history.
Successful treatment of polyhydramnios with indomethacin in a preg-
nancy at risk for Bartter syndrome. C. Hughes, AR. Rosenberg, G.
Kainer, T. Tait, Department of Nephrology, Prince of Wales Children's
Hospital, Sydney, N.S.W. 2031 and Tamworth Base Hospital, Tam-
north NSW, Australia. The features of Bartter syndrome in the neonate
include not only hypokalemia, alkalosis and hyperreninemia, but also
severe polyuria, hypercalciuria, nephrocalcinosis and growth retarda-
tion. The prostaglandin synthetase inhibitor, indomethacin, partially
corrects most of these abnormalities. Indomethacin has also recently
been used for tocolysis in premature labor instead of beta sympatho-
mimetics and, while there appears to have been no increase in fetal
mortality, there have been reports of side effects including reduction of
fetal urine output, transient post-natal renal insufficiency and oligohy-
dramnios. Further, there are occasional reports of the use of indometh-
acm in the treatment of polyhydramnios. We report a case of extreme
polyhydramnios during early pregnancy in a 34-year-old woman whose
first child was known to have Bartter syndrome. Because obstetric
opinion indicated that there was a high risk of premature labor with
delivery of an extremely low birth weight infant, the mother was treated
with indomethacin 200 mg/day commencing at 27 weeks gestation. The
polyhydramnios decreased and only worsened again when indometh-
acm was ceased 10 days before delivery. The infant's post-natal course
was marked by transient renal failure (creatinine 0.21 mniol/liter) and
subsequently, by the development of characteristic features of Bartter
syndrome. This is the first occasion that indomethacin has been used to
treat polyhydramnios due to fetal Bartter syndrome. Its effectiveness in
this case is further evidence that indomethacin reduces polyhydramnios
by causing a reduction in fetal urine output.
Is mesangial proliferative glomerulonephritis a relatively common
cause of childhood nephrotic syndrome in the Arabian Gulf? M.B.
Abdurrahman, A.T.H. Elidrissy, K. Mahmoud, S. Al Rasheed, M. Al
Mugei,'in, Departments of Paediatrics and Pathology, College o.f
Medicine, Rivadh, Saudi Arabia. To evaluate the significance of
mesangial proliferative glomerulonephritis (MesPGN) as a cause of
childhood nephrotic syndrome, we analyzed 126 consecutive children
presenting with the nephrotic syndrome in King Khalid University
Hospital, Riyadh. All patients with nephrotic syndrome and atypical
clinicopathologic features and/or response to corticosteroid therapy
were biopsied. MesPGN was found in 24 of 69(35%) percutaneous renal
biopsies, giving a frequency of 19% of all children with the nephrotic
syndrome. Compared to patients with mirtimal chaLnge nephrotic syn-
drome, MesPGN patients were predominantly males (20 M vs. 4 F), and
had increased frequency of microhematuria, steroid dependence or
resistance, renal impairment and presence of 1gM immunofluorescence
in the mesangium. We speculate that the increased prevalence of
MesPGN in childhood nephrotic syndrome in the Arabian Gulf may be
an expression of intense antigenic stimuli, including infections and
infestations.
Standardized predicted creatinine clearance (SPCcr)—An improved
method for PCr fromserum creatinine (Sr)•R.S. Nanra, 5K. Nanra,
M. Jones, H. Paul, Department of Nephrology, Royal Newcastle
Hospital, Newcastle, NSW, Australia. The Cockroft and Gault formula
for PCr was modified to improve the predicted result and to use the
formula for patients with extremely low and high body weights (BW). In
the SPCCr formula, true BW was replaced by optimal BW calculated
from height and optimal Body Mass Index (22.5 kg/M2):
[(140 —. Age) ' 22.5 ' Ht M2]
SPC,. for males
Sc mmol/Iiter)]
SPCcr for females = Formula for males ' 0.85. GFR was calculated in
67 females and 52 males and by the standard Cr51.EDTA plasma
clearance method, and compared with the PCr and SPCCr. The age
range of the patients was 18 to 80 years and BW range 46 to 140 kg. The
correlation coefficients 'r' forPCCr/GFR and SPCcr/GFR were 0.81 and
0.91, respectively. Comparison of methods was according to the
statistical techniques described by Altman and Bland (The Statistician,
32:307—3 17, 1983). The plots of individual differences (A — B) against
the average (A + B)/2 for PC, and SPC. gave 'r' values of 0.18 and
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0.06, respectively, indicating independence of the between-method
differences and the size of the measurements. The mean of the
individual (A — B) differences (relative bias) and their standard devia-
tion (error) for PCCrIGFR was 5.9 SD 24.6, and for SPCCr was —0.7 SD
10.1; the paired 't' test value for PCC,JGFR was 2.593 (P < 0.02) and for
SPCcrIGFR was —0.797 (P < 0.5 > 0.2). Conclusion: SPCCr gives a
better estimation of GFR than PC. and overcomes difficulties associ-
ated with extremes of BW.
Kindergarten screening program for detection of renal disorders. CM.
Lamb, J. Paxton, S.J. Harris, R.J. Hogg, P.H. Henning, N. Wigg,
K.F. Jureidini, Renal Unit, Adelaide Children's Hospital, Adelaide,
South Australia 5006, Australia. In a pilot study, 1803 kindergarten
children were screened for renal disease by testing of frozen first-
morning urine specimens and measurement of blood pressures and
growth percentiles. Urine specimens were tested by dipstick for hema-
tuna, proteinunia and glycosunia, and assayed for urinary beta-2 micro-
globulin. The screening abnormality rate was 9.1% (blood pressure
>95th percentile for age 5.0%, elevated beta2-microglobulin 2.0%,
proteinuria and/or hematuria 1.0%, height significantly <3rd percentile
1.0%). Identified children were followed up by clinical investigation,
repeat urine assays and renal ultrasound where indicated. On review,
22% of those detected as hypertensive demonstrated persistent hyper-
tension requiring further investigation. A number of children with
significant renal tract abnormalities were detected, including nephritis
(2), vesicouretet-ic refiux (2), persistent hematuria (4). Other abnormal-
ities detected were growth hormone deficiency (I), borderline hyper-
calciuria (I). The study suggests that this screening program is effective
in detecting renal abnormalities. Compared to other renal screening
programs, the use of frozen first-morning urine specimens reduces the
false positive rate for proteinunia and hematuria, and facilitates urine
collection.
Long-term follow-up of infants with gross vesico-ureteric reflux R.R.
Bailey, K.L. Lynn, A. Smith, Department of IVephrology, Christchurch
Hospital, Christchurch, New Zealand. The majority of infants (l yrof
age) presenting with gross vesico-ureteric refiux (VUR) already have
renal damage at the time of presentation or develop reflux nephropathy
(RN) during the first few years of life. We report the long-term
follow-up of3l patients (16 boys) presenting in infancy with gross VUR
between 1952 and 1970. They had a total of 44 grossly refluxing ureters
(13 bilateral, 18 unilateral) and presented between 1 day and 48 weeks
of life (mean 15.3 weeks). Twenty-four presented with a urinary tract
infection. Of the 31 infants originally enrolled, 5 died within the first
year of life, 4 were followed for up to II years before being lost to
follow-up, and I was killed in a motor vehicle accident after 19.5 years
of follow-up. The remaining 21 patients have been followed far 16—37
years (mean 23.7 years). Thirteen of these 21 had a total of 19 surgical
procedures (18 ureteric reimplantation; I ureteric diversion) after RN
was demonstrated. At follow-up 4 had normal kidneys, 13 unilateral RN
and 4 bilateral RN. Of those with unilateral RN, 2 have a diastolic blood
pressure 90 mm Hg and I proteinunia. Two of the 4 patients with
bilateral RN have proteinunia and renal insufficiency, with one pro-
gressing towards end-stage. Infants who present with grass VUR
appear to do well if free of severe bilateral RN at presentation. Patients
with RN should remain under regular nephrological supervision with
particular attention given to proteinuria, renal function and blood
pressure. Since this study has been in progress 24 patients born
between 1952 and 1970 have entered our renal replacement program
because of end-stage reflux nephropathy. These patients came to
attention with hypertension, proteinuria or renal failure and did not
present in childhood with urinary infections.
Non-dilated urinary tract obstruction. CA. Somerville, R. Chmiel,
B.F. Murphy, Departments of Nep/irology and Nuclear Medicine, St.
Vincent's Hospital, Fitzroy 3065, Australia. The initial diagnosis of
obstructive nephropathy is generally made by the demonstration of a
dilated collecting system. Non-dilated obstruction has been previously
described but is poorly recognized by clinicians. We describe the
clinical features of five cases of non-dilated obstructive nephropathy
observed aver a three year period. All patients were uremic on
presentation. Obstruction was caused by retro-penitoneal malignancy in
two cases and uric acid lithiasis in the remaining three cases. All
patients had at least one ultrasound examination. Isotope renography
and computed tomography were performed in 3 and 4 of the cases,
respectively. None of these imaging techniques suggested obstruction
in any of the cases, Nucleotide scans were characterized by unusually
poor perfusion and parenchymal phase images when compared to scans
in dilated obstructive nephropathy. in all five cases, however, an
immediate diuresis and rapid return of normal renal function occurred
following relief of obstruction. The absence of dilatation in obstruction
nephropathy is uncommon but may be responsible for delayed diagno-
sis and management of a readily treatable cause of acute renal failure.
Whitaker hook disruption of posterior urethral valves PA. Dewan,
M.D. Dinneen, PG. Duflv, PG. Ransley, Urology Depart ment, Hos-
pital for Sick Children, Great Ormond Street, London, United King-
dom. Since 1985, 44 patients have had posterior urethral valves
disrupted with a Whitaker diathermy hook. Twenty-seven patients had
an abnormal prenatal ultrasound, of whom 22 were seen in the first
week of life. Overall, 31 boys presented in the first two weeks of life.
The urethral valves were hooked as soon as the patient was metaboli-
cally stable, 41 under a general anesthetic; 16 had urethral endoscopy as
part of an anatomical review, and, electively, two of these had
additional concurrent elective endoscopic diathermy. Of the 42 "hook
only" patients, six required early post-hook intervention for infection
and/or poor renal function (vesicastomy-2; rehook-2; resection-2). To
date 30 of 36 boys, whose only early treatment was with a Whitaker
hook, have come to endoscopic review at 3 months. In three cases no
further diathermy was required as the valves appeared to have been
completely destroyed by the previous hook procedure. In 27, the
remaining valve tissue varied from minor lateral folds to split, but
complete, valve remnants. Only one of these patients showed a
subsequent improvement in renal function, suggesting that the others
had had their outflow obstruction relieved by the Whitaker hook. Minor
extravasation was seen in one case, but no strictures have occurred.
Whilaker hook diathermy of posterior urethral valves allows safe
manipulation of the neonatal urethra, in a disease that now commonly
presents for early surgical management.
Acute renal vein thrombosis in a transplant kidney: Successful salvage
with intra-arterial streptokinase. W.E. James. J. Taylor, C.J. Doecke,
M. Cochran. Department of Nephrology, Flinders Medical Centre,
Bedford Park, SA, 5042, Australia. The management of acute renal vein
thrombosis (ARVT) remains controversial. Thrombolytics have in-
creasingly found a role when renal function is compromized. We report
the salvage of renal function after lysis of an ARVT. This was achieved
by direct infusion of low dose streptokinase and hepanin into the artery
of a renal allograft. To our knowledge this is the first report in a
transplant kidney concerning this method. A 34-year-old male with an
unclassified glomerulonephritis received a cadavenic graft after six
months of maintenance hemodialysis. Week four post-operation his
plasma creatinine rose from 0.15 mmol/liter to 0.5 mmol/liter despite a
course of methylprednisolone. Renal biopsy showed predominantly
parenchymal edema. A renal vein thrombosis was diagnosed angio-
graphically; the arterial catheter was left in place. Forty hours post-
biopsy, streptokinase (5000 U/hr) and heparin (80 U/hr) were infused for
64 hours. Renal function improved dramatically, plasma creatinine fell
from 0.724 mmol/liter to 0.206 mmol/liter at discharge. Clot lysis was
confirmed by angiography. However, within one week, he had an
episode of severe vascular rejection which was refractory to further
treatment with resultant graft loss. A venogram at the time showed a
patent renal vein. Low-dose thrombolytic therapy is ideally suited to
the treatment of ARVT because of the reduction in systemic complica-
tions of fibrinolytic therapy, and the ability to lyse clots quickly and
thus salvage a compromized kidney. Our experience lends further
support to regional low dose thrombolytics in native and transplanted
kidneys.
Hyperparathyroidism and the response to recombinant human eryth-
ropoletin (rHuEPO) in dialysis-dependent children P.H. Henning, S.
Owen, K.F. Jureidini, Renal Unit, Adelaide Children's Hospital, South
Australia 5006, Australia. Impaired responses to rHuEPO have been
associated with a number of well recognized factors. Parathyroid
hormone (PTH) inhibits erythropoiesis in vitro, but clinical evidence
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has been lacking. We report the treatment of five highly transfusion-
dependent children aged 11 years (8.3—12.2) with intravenous rHuEPO,
two of whom may have had an impaired response due to severe
secondary hyperparathyroidism. All children had been receiving hemo-
dialysis thrice weekly for at least three months via an A-V fistula. All
were anemic, mean Hb 6.6 g/dl (5.6—7.3) requiring transfusion every 4—6
weeks. rHuEPO was given after each dialysis session, beginning at a
dose of 75 U/kg/week and increased until a target Hb of 10—12 g/dI was
achieved. Three children were treated for 52 weeks, one for 44 weeks,
and one for 23 weeks. Two patients sustained the target Hb throughout
the study, while three demonstrated an impaired response for a signif-
icant period, in spite of high doses of rHuEPO (300 U/kg/week). Of the
three with a period of impaired response, only one had evidence of iron
deficiency, while two had severe hyperparathyroidism (intact PTH >65
pmol/liter; NR 2—6). with elevated alkaline phosphatase and x-ray
changes. A period of lower levels of PTH (<35 pmol/liter) in these two
were associated with a clear improvement in response to rHuEPO. No
other recognized cause for reduced hemopoiesis was evident, and PTH
levels were normal in the other patients. We believe that very high
levels of PTH may be causally related to a poor response to rHuEPO.
Captopril does not protect against renal oxidative injury. S.A. Chin,
J.P. Fawcett, R.J. Walker, Departments of Pharmacy and Medicine,
Otago Medical School, Dunedin, New Zealand. Captopril has been
reported to provide protection against ischemia-reperfusion injury in rat
myocardium (de Graeff PA et al, Am J Med 84:(Suppl 3A), 67—74, 1988).
This action has been ascribed to the thiol group of captopril which may
act as a free radical scavenger preventing oxidative injury. This has not
been investigated in the kidney. This study compared the potential
protective role of captopril (C, 6 mg/kg/day), enalaprilat (E, a non-thiol
containing ACEI, 3 mg/kg/day), or N-acetylcysteine (NAC, 10 mg/kg/
day) administered intraperitoneally to rats (N = 5 per group) for 5 days.
Renal homogenates were incubated at 370 for I hour with tert-butyl
hydroperoxide (TBH) (0.2 mM) to induce oxidative injury. Lipid
peroxidation at one hour was measured as the amount of malondialde-
hyde (MDA) formation and expressed as nmol/nig protein. Results are
the mean SEM, 3 expts (N—24).
Contr. C E NAC
7.25 (0.21) 8.63 (0.17)° 7.26 (0.16) 7.49 (0.14)
P < 0.001 vs. control
Captopril added in vitro at concentrations from 10 M to 100 LM did not
alter TBH-induced lipid peroxidation compared to control. Captopril in
vivo, is highly bound to cellular proteins and glutathione by disulphide
bonds. Glutathione is the main source of cellular thiol groups and
protects against cellular injury. Thus, the enhanced oxidative injury
demonstrated could be due to the removal of free glutathione. in this
model enhanced lipid peroxidation seen with captopril in vivo suggests
that captopril does not act as a free radical scavenger.
Reversibility of cyclosporine (CsA) induced glomerular capillary hyper-
tension. P. Magner, R. Chea, 0. Bathe, L. Paul, Department of
Medicine, University of Calgary, Calgary, Alberta, Canada. Elevations
in glomerular capillary pressure (Poc) may be important in progressive
renal injury. CsA use is associated with progressive renal damage and
an increase in renal vascular resistance, but its effects on glomerular
hemodynamics are not well characterized, in rats P0. is elevated when
doses are used that achieve serum CsA levels comparable to those
attained clinically, in contrast to the low or normal PGc when high doses
are given. We now report glomerular hemodynamic measurements after
CsA has been discontinued. Female Munich-Wistar rats were given
subcutaneous CsA 15 mg/kg/daily for 2 weeks, a dose that achieves
serum levels of 500 130 ng/ml. After 2 weeks of CsA, one group was
micropunctured while the second group had the CsA discontinued and
were micropunctured 2 weeks later. Untreated normal and cremophor
treated rats were studied as controls. Data from rats receiving high dose
CsA (30 mg/kg/day) are included for comparison.
Group N Weight MAP P0 B
Normal 4 192 4 116 6 44.4 2.3 13.3 0.7
Cremophor 7 184 5 109 3 41.4 0.6 14.7 1.3
CsA 30mg/kg 12 164 5 106 5 40.1 0.7 13.9 0.9
CsA 15 mg/kg 6 175 8 116 6 54.3 2.7' 14.9 1.9
CsA 15-recovery 7 166 3 122 8 39.3 09b 15.4 1.2
Data are means sEM; P < 0.05 vs. other groups; b NS vs. normal
and cremophor. Abbreviations are: MAP, mean arterial pressure; PGC
glomerular capillary pressure; PB: Bowman's space pressure, mm Hg.
Short term administration of CsA to rats in doses that attain levels
comparable to those achieved clinically induces glomerular capillary
hypertension, which is reversible after stopping the drug. The long-term
effects of CsA on glomerular hemodynamics, their reversibility, and the
effects of other interventions remain to be tested.
Characterization of an unique human glomerular antigen [7-SQ/A] and
its quantification in urines of patients with kidney disease. R. Kittel-
herger. Ti. Neale, Department of Medicine, Wellington School of
Medicine, Wellington, New Zealand. CerLain non-basement membrane
glomerular capillary wall antigens are known targets for auto- or
heterologous antibodies in in situ experimental models of GN. In an
attempt to establish human relevance for these models we have
produced a panel of 12 monoclonal antibodies (McAb) with specificity
for non-glomerular basement membrane capillary wall antigens (Hy-
hrido,na 1990, in press). One such McAb, designated 7-5Q/McAb,
reacts exclusively with kidney exhibiting specificity for glornerular
epithelial cell membranes and proximal tubule brush border as localized
by immunogold electron microscopy. We have purified the correspond-
ing cell membrane antigen by immuno-affinity chromatography and
characterized it as an acidic membranous glycoprotein of Mr 98/105 kD
by amino acid analysis and lectin typing. Few glomerular cell-surface
proteins (mainly of animal origin) have been characterized to date: gp
330 (Heymann's antigen), podocalyxin, podoendin, dipeptidyl peptid-
ase IV (DPP IV) and a sialoglycoprotein SGPIO7/1 15. The latter and
DPP IV have similar Mr to 7-5Q/A but in contrast are not kidney-
specific. Furthermore, SGP 107/115 is a sialoglycoprotein, while 7-SQ/A
contains no sialic acid. Pure 7-SQ/A was used to raise antisera in
rabbits. Polyclonal antibodies were obtained after caprylic acid and
ammoniumsulfate precipitation, designated 7-SQ/PcAb. The possibility
that 7-SQ/A is identical to DPP IV was excluded by a) attempts at
inhibition of the DPP IV substrate reaction with antibodies to DPP IV
and 7-SQ/McAb and 7-SQ/PcAb; b) blotting of TX-I 14 extract and pure
7-SQ/A with these antibodies, c) DPP IV substrate reaction of TX-I 14
extract and pure 7-SQ/A and d) blocking studies by IF on normal human
kidney. While anti-DPP IV inhibited the enzyme reaction, 7-SQ/McAb
and PcAb did not. On blots anti-DPP l\ reacted with TX-ll4 extract
only while 7-5Q/McAb and PcAb reacted with TX-1l4 extract and
7-SQ/A. Strong substrate reaction was obtained with TX-1l4 extract but
not with pure 7-SQ/A. Anti-DPP IV did not block 7-SQ/McAb IF
reactivity. Both antibodies to 7-5Q/A and the pure antigen were used to
develop a sandwich ELISA covering a range of 11—220 ng/ml. From
urines of 60 patients with various kidney diseases and 27 normal
subjects, 6 patient urines showed 7-SQ/A-levels above II ng/ml. None
of the normal urines was positive. 7-SQ/A is an unique, new renal
antigen with relevance in human kidney disease.
Heterogeneity of macrophage phenotype in the kidney in experimental
glomerulonephritis (GN). H. Y. Lan, D.J. Paterson, P. Hutchinson,
R.C. Atkins, Department of Nephrologv, Prince Henry's Hospital,
Melbourne, 3004, Australia. Macrophages in different tissues and body
cavities are heterogeneous in morphology, enzyme activity, secretory
products and surface phenotype, hut it is not known if this heteroge-
neity reflects the existence of different stable lineages. Using a model of
Goodpasture's syndrome induced by ariti-GBM antibody in rats, we
addressed this issue by applying MoAbs to (I) analyze the heterogene-
ity of CD4 antigen expression on macrophages isolated from the renal
interstitium, lung and lymphoid tissues by two color flow cytometry;
and (2) determine, using immunohistochemistry, the heterogeneity of
expression of other macrophage antigens in the inflamed kidney com-
pared with inflammatory macrophages in the lung. The main findings
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were: (1) CD4 antigen (W3/25) expression on OX-424 macrophages
varied in different tissues. They comprized 87 4.2% of the total
leucocytes in the renal interstitium, 76 6.8% in kidney lymph nodes,
35 3.0% in spleen, 16 2.1% in peripheral blood, and 14 2.3% in
the lung. (2) Heterogeneity of macrophages in the renal interstitium was
seen with respect to EDI and OX-42 antigen expression. The use of
either EDI or OX-42 MoAbs alone only recognized 53% or 61% of
macrophages labelled by a mixture of the two MoAbs. However, this
heterogeneity of macrophage population was not found in the glomer-
ulus and lung during the disease, suggesting that EDI and OX-42
MoAbs recognized different macrophage subpopulations in the renal
interstitium, but not in the glomerulus and lung. These results indicate
that renal interstitial maerophages and/or DC are highly heterogeneous
in the expression of antigens recognized by the W3/25, OX-42 and EDt
MoAbs; and that this heterogeneity may reflect differential functional
states of macrophages in different tissue microenvironments.
Experience with ANCA ELISA for the diagnosis of systemic small vessel
vasculitis. J.A. Savige, L. Cliang, J.D. Porkin, Repatriation General
Hospital, Heidelberg West, Victoria 3081, Australia. Anti-neutrophil
cytoplasm antibodies (ANCA, anti-myeloperoxidase and anti-elastase
antibodies) are commonly found in Wegener's granulomatosis (WG)
and microscopic polyarteritis (MPA). We tested sera from 393 patients
in whom a vasculitis was suspected clinically. Ninety-one (23%) of
these were positive in the ANCA ELISA, a further 57 (16%) were
positive in the assay for anti-myeloperoxidase antibodies, and 35 (16%)
in the assay for anti-elastase antibodies. A total of 125 (32%) sera were
positive for antibodies against neutrophil cytoplasm constituents.
Eleven of 15 (73%) sera with histological evidence of WG and 18 of 20
(90%) sera from patients with MPA were positive in these assays. No
ANCA, anti-myeloperoxidase or anti-elastase antibodies were detected
in 20 convalescent sera from patients either with WIll or MPA or who
had previously been positive. The mean time between positive and
negative sera was 8 weeks (range 3 weeks to 6 months) and 2 of 3
patients who relapsed, developed ANCA of the same specificity as the
original sera. Of the 146 sera also tested for anti-IIIBM antibodies. 12
(8%) were positive and 49 of 74 (66%) sera tested for ANA were
positive. ANCA, anti-myeloperoxidase and anti-elastase antibodies are
common in patients in whom a vasculitis is suspected on clinical and/or
histological grounds.
Urinary platelet factor four (PF4) levels are raised in mesangial IgA
glomerulouephritis (IgAGN), but not in thin basement membrane disease
(TBMD). K. Toiro, T.D. Hewitson, P. Kincnid-Smith, Department of
Nephrology, Royal Melbourne Hospital, Victoria 3050, Australia. PF4
is a protein which is released by activated platelets. The concentration
of PF4 IPF4] in urine was determined by an Enzyme-Linked Immu-
nosorbant assay (ELISA) in patients with IgAGN (N 80), TBMD (N
= 37), membranous nephropathy (MN) (N = 13), minimal change
nephrotic syndrome (MCNS) (N 3), and in healthy controls (N = 20)
and compared with urinalysis and renal function. An immunoper-
oxidase method was used to examine urine sediments for the presence
of platelets. Urinary PF4 was detected in 33 out of 80 patients with
1gAGN (median 0.15, range 0.07—2.5 ng/ml, N 33), in only 2 out of 37
patients with TBMD (P < 0.005), and in no patients with MN, MCNS,
or in healthy controls. A positive correlation between urinary PF4
levels and red blood cell counts was observed in patients with 1gAGN
(r = 0.876, P <0.001), but not in TBMD. (PF4] did not correlate with
proteinuria or plasma creatinine. Platelets were detected in urine in II
out of 15 patients with IgAGN hut in only I out of 10 patients with
TBMD. Urinary red blood cell counts in all these patients were over
100,000/mI. Elevated urinary PF4 may indicate platelet activation in
glomernli in IgAGN with severe hematnria. Conversely, results suggest
that platelet activation is not involved in TBMD hematuria. These
results suggest that urinary PF4 levels may be a useful parameter in
distinguishing these diseases, both of which commonly present with
microscopic hematuria as an isolated abnormality.
Post-renal transplant (TX) limb pain: A case-control study. L. Pien-
dcc, M. Thomas, G. Carroll, Departments of Nephrology and Rheu-
matology, Royal Perth Hospital, Perth, WA 6000, Australia. Unex-
plained symmetrical limb pain in cyclosporine (C5A)-treated Tx
patients has been recently recognized. To determine possible predis-
posing factors, a retrospective case-control study was performed.
Eleven such renal Tx patients were identified by consultant recall. Ten
CsA and 10 non-CsA-treated control Tx patients were identified from
ANZDATA records, with a similar distribution of primary diseases.
Limb pain occurred in 2/127 Tx 1972—1983 (pre-CsA) vs. 9/137 Tx
1985—1990 (post-CsA). at 3.0 1.8 months post-Tx. Pain was located in
ankles/feet (II), knees (5), and upper limbs (2) associated with signs of
local inflammation (5), periosteal neostosis (4) and increased radio-
isotopic uptake. Transiliae bone biopsies showed non-aluminium osteo-
malaeia (3/3). Pain remitted spontaneously with radiological deminer-
alization over 1—2 years; ealeitonin brought pain relief in 2—4 days with
decreased isotopic uptake, and relapse on cessation. Compared to CsA
and non-CsA treated controls, limb pain patients tended to have had a
longer duration of dialysis pre-Tx and more advanced hyperparathy-
roidism (higher pre-Tx intact PTH and alkaline phosphatase, higher
incidence of previous parathyroidectomy) but differences did not
achieve statistical significance. Six months post-Tx, limb pain patients
had higher serum alkaline phosphatase concentrations than controls
1321 (112—1420) vs. 142 (31—866) U/I, median (range), P 0.04, ranked
sum] and tended to more rejection episodes and higher intact PTH than
controls. Post-Tx limb pain syndrome is associated with elevated serum
alkaline phosphatase and possibly more advanced pre-Tx renal bone
disease.
Early ischemic cardiac mortality in elderly renal allograft recipients. L.
Carey, C. Hawley, B. Menzies, J. Petrie. R. Righy, J. Burke, 1. Hardie,
D. Wall, R. St,'ong, S. Lynch, P. Woodruff, J. Quinn, Renal Unit,
Princess Alexandra Hospital, Brisbane. Queensland, 4/02, Australia.
Isehemic cardiac mortality was examined in a retrospective study of all
374 renal allograft recipients in our unit between August 1983 and
August 1988, and followed to July 1990. The mean age of the patients at
the time of transplant was 44.3 years (range 2—68 years), and the
patients were followed for a mean of 50.6 months (range 22—82 months).
Isehemic cardiac mortality increased with increasing age. In the 51—60
year age group there were 24 deaths in 107 patients, cardiac mortality
accounting for 33.3% of the deaths, and in the group 61 years and over,
there were 10 deaths in 37 patients, 60% of the deaths being attributed
to isehemic cardiac events. In the 51—60 years group, the deaths were
scattered throughout the study period, but in the 61 and over group,
four and of six of the deaths due to isehemie cardiac events occurred
within three months of the transplant. The majority of patients 10/14
(71%) who died of isehemie heart disease had either a history consistent
with, or risk factors (other than those directly related to the renal
disease) for coronary artery disease. As a result of this study we
advocate careful screening for coronary artery disease in patients being
selected for renal transplantation, particularly in patients over 60 years.
This should lead to a reduction in death from obstructive coronary
lesions at the time of transplant and post-transplantation, and to more
cost-effective utilization of the limited supply of donor kidneys.
Superoxide anion, hydrogen peroxide and hydroxyl radicals are gen-
erated in rat kidney slice cultures containing puromycin aminonucleoside.
S.D. Ric'ordo, i.E. Bertrom, G.B. Ryan, Deportment of Anutotny,
University of Melbourne, Purkville, Victoria 3052, Australia. Reactive
oxygen species (superoxide anion, O,, hydrogen peroxide, H202;
hydroxyl radical, 'OH) have been implicated as mediators of pnromyein
aminonueleoside (PAN) nephrosis in rats. Major alterations to glomer-
ular epithelial cell (GEC) ultrastrueture are seen in PAN nephrosis,
including the replacement of foot processes with flattened expanses of
cytoplasm. We have previously shown that PAN produces major
alterations in the structure of GECs in rat kidney slices in vitro
(Bertram et al, Cell Tissue Res 260:555—563, 1990). The present study
measured levels of 02', H202 and 'OH in rat kidney slice cultures
containing PAN. Rat kidneys were perfused with Hanks' Balanced Salt
Solution, removed, and cut into I mm slices. The slices were incubated
for 3 hours in Medium 199 with Hanks' salts (control), or in Medium 199
with Hanks' salts containing PAN (100 jzg/ml) with or without the
addition of superoxide dismutase (a 02' scavenger), eatalase (which
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reduces H,O, to H,O), or desferrioxamine (an iron chelating agent that
inhibits 0H generation). All three reactive oxygen species were
generated in the PAN cultures. Peak levels were: O,', 2.4 M after 25
minutes; H,O,, 0.19 /LM after 20 minutes; and 'OH, maximal absorb-
ance at 532 nm after 105 minutes in culture. When superoxide dismutase
(450 U/mI), catalase (100 g/ml) and desferrioxamine (2 mM) were
added separately to PAN cultures, O,', H202 and 'OH were removed.
respectively. Neither 0,' . H,0, nor 'OH were generated in control
cultures (Medium 199 with Hanks' Salts). These results indicate that
°2, H,02 and 'OH are generated in rat kidney slice cultures contain-
ing PAN. Studies on the possible protective effects of reactive oxygen
species scavenging enzymes and antioxidants on GEC ultrastructure in
PAN cultures are in progress. These experiments should provide more
information on the role of reactive oxygen species in PAN-induced
GEC injury in vitro, and PAN nephrosis in vivo.
D.. and L-lactate absorption from continuous venovenous hemodiafil-
tration (CVVHD) for acute renal failure. M. Thomas, G. Leslie, C.
Ducat, J. Blennerhasset, Renal Unit, Royal Perth Hospital, Perth, WA
6000. Australia. To determine quantitative absorption of L-lactate and
the nonphysiological isomer D-lactate from lactate-buffered dialysate. 4
patients with multi-organ failure on CVVHD were studied. Sterile
hemofiltration solution containing 22.5 mmol/liter of both D- and
L-lactate as dialysate was utilized; intravenous replacement fluid was
normal saline for 8 hours prior and throughout each study period,
changing to hemofiltration solution for the final 40 minutes. Plasma (Vb)
pre- and post-filter and dialysate samples were taken at 20 minute
intervals at blood flow rates (Qb) of 100. 150 and 200 mI/mm and
dialysate flow rates (Qd) of 0, 500, 1000 and 2000 ml/hr; flow rates were
altered every 40 minutes. D- and L-lactate concentrations were assayed
by colorimetric enzyme assay, expressed in mmol/liter, mean sn, N
= 8, for Qb = 100 mI/mm.
Qd Pre-filter Vb Post-filter Vb Dialysate & UF
ml/hr L-lact D-lact L-lact D-lact L-Iact D-lact
0 1.3 0.2 0.0 0.0 1.6 0.7 0.0 0.0 1.9 1.1 0.0 0.0
1000 1.9 0.7 0.7 0.5 5.2 1.2 3.9 0.8 4.7 0.6 3.8 0.7
2000 2.2 0.7 1.0 0.5 6.2 1.3 5.8 0.9 8.0 1.6 6.8 0.9
Supplement
Osmoprotectant
NaCI
0
GB
GB
0
Tre
NaCl
0.6 M
GB
GB
0
Trea
NaCI
0.6 M
GB
GB
l0 M
Trea
E. coli (N = 6) 0 0 0 88.4 46.6 52.8
K. pneu,noniae (N = 5) 0 0 0 59.8 24.0 41.8
Enteroha c/er (N = 5) 0 0 0 32.2 22.2 25.4
Ps aeruginosa (N = 5) 0 0 0 9.8 13.0 6.0
Mean values in mmol/mg dry weight of bacteria
The ability to accumulate GB and Tre was common to all tested strains
and rapid growth under osmotic stress was associated with higher Tre
and GB levels. We postulate that Tre and GB mechanisms are essential
in the pathogenesis of UTI.
The gene for the Goodpasture antigen is present in patients with
Alport's syndrome. J.A. Savige, Repatriation General Hospital, Heidel-
berg West, Victoria 3081. Australia. In X-linked Alport's syndrome, the
Goodpasture antigen appears to be absent from the basement mem-
branes of the glomerulus and presumably also from the tubules, lens
and cochlea. We have used the technique of polyrnerase chain reaction
amplification to determine whether the gene for the Goodpasture
antigen is present in Alport's syndrome. 1)NA samples from 6 unrelated
individuals with Alport's syndrome, who had been transplanted for
renal failure, were examined. The diagnosis of Al port's syndrome was
made on the characteristic electron microscopic appearance of the renal
basement membrane (N = 4), the presence of sensori-neural deafness(N = 4), a family history of Alport's syndrome (N = 5) and the presence
of circulating inhibitable anti-GBM activity post-transplant (N = 2).
Oligonucleotides (20 mers) corresponding to the 5' and 3' ends of the
known 25 amino acid sequence for the putative Goodpasture antigen
were used as primers for amplification of genomic DNA. The products
were then blotted and probed with an intermediate 19 mer. DNA from
all Alport's patients contained a 75 base pair fragment con'esponding to
the non-collagenous domain of the alpha 3 chain of type IV collagen,
suggesting that a large deletion of the putative Goodpasture antigen is
unlikely to account for the defect in Alport's syndrome. We have shown
in an analogous fashion that the corresponding region of the alpha 4
chain of type IV collagen is also present in these patients.
Addition of IV hemofiltration solution increased pre-filter L-lactate 10%
and pre-filter D-lactate 50%. Fractional absorption, calculated as the
fractional fall in delivered dialysate lactate concentration corrected for
ultrafiltration (U F), fell from 75% to 50% of delivered dialysate D- and
L-lactate with increasing Qd. increasing Qb from 100 to 200 mI/mm
reduced post-filter Vb D- and L-lactate by 30% with no consistent effect
on lactate concentration at other points or fractional absorption. This
study has demonstrated measurable alterations in plasma lactate con-
centrations from CVVHD, determined predominantly by dialysate flow
rates. This requires review of the use of lactate as a monitor of clinical
status in acute renal failure treated by CVVHD.
Osmoprotectants in urinary tract pathogens under osmotic stress. B.A.
Peddie, S.T. Chambers, M. Lever, Departments of Nephrology, Infec-
tious Diseases and Pathology. Christchurch Hospital, Christchurch,
New Zealand. Adaptation of bacteria to fluctuating osmolarity is
fundamental to their survival. The osmoprotectants for E. co/i are
glycine betaine (GB) and trehalose (Tre). The role of these in other gram
negative bacteria has not been established. The importance of osmo-
protectants in UTI is yet to be studied. Accumulation of GB and Tre in
response to osmotic stress has been measured in gram negative urinary
pathogens using HPLC methods. isolates of E. coIl, K. pneumoniae,
Enterobacter spp. and Ps aeruginosa were grown in a chemically
defined medium supplements of NaCI (0.6 M) and GB (l0- M). Log
phase cultures were harvested. Addition of 0.6 M salt to the medium
retarded growth in all strains. Growth rates of E. co/i and K. pneumo-
niae in 0.6 M NaCI were restored by the addition of GB, while those for
Enterohacter were improved and for Ps aeruginosa slightly better.
Diclofenac-associated interstital mucinosis (DAIM): A cause of acute
renal failure. J.P. Dowling, N.M. Thomson, J. W. Agar, Departments of
Tissue Pathology and Nephrology, Prince Henry's Hospital Melbourne
and Consultant Nephro/ogist, The Geelong Hospital, Australia. Non-
steroidal anti-inflammatory drugs are responsible for a variety of renal
side effects, among which renal impairment is common and considered
due either to vasomotor or interstitial inflammatory changes. Recently
four patients, I female (41 years old) and 3 males (31,45,46 years old),
developed reversible renal failure associated with ingestion of di-
clofenac. Three patients presented within 1-3 days of ingestion of 1-3
diclofenac tablets taken to relieve pain; a fourth patient (male 46 years
old) had been taking this medication regularly for months prior to
presentation with RF. Renal biopsies all showed accumulation of
excess colloid-iron positive rnucopolysaccharide, mostly hyaluronic
acid in the interstitium, particularly the medulla, associated with a light
mixed inflammatory infiltrate in the interstitium: one biopsy from the
male 31 years old, showed degenerative changes deep within the
medulla, probably related to early papillary necrosis. A review of 30
biopsies showing primary interstitial pathology, including other drug-
related lesions and sarcoidosis, and 10 biopsies showing glomerulone-
phritis-related interstitial inflammation revealed that light focal mucin
accumulation frequently accompanied interstitial inflammation, but the
amount did not approach that seen in DAIM. Three of 30 with primary
interstitial disease had similar heavy mucin but the cause of the
interstitial nephritis in these patients was unknown. The interstitial
mucin accumulation which may result from diclofenac stimulation of
interstitial fibroblasts may contribute to the pathogenesis of the renal
functional impairment in these patients by preventing water and solute
exchange due, particularly, to the water-holding capacities of the
glycosaminoglycans.
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Urinary tract abnormalities detected by antenatal ultrasound. iC.
Tam, E.M. Hodson, SM. Gruenewald, KG, Cohen, Departments of
Paediatrics, Paediatric Surgery and Nuclear Medicine and Ultrasound,
Westmead Hospital, Westrnead, NSW, 2145, Australia. Urinary tract
abnormalities were detected antenatally in 33 babies by ultrasound.
Twenty babies were born in II months at Westmead Hospital giving an
incidence of 0.5%!; the other 13 were referred from elsewhere. Antena-
tally 26 babies had hydronephrosis and 7 (2 stillbirths) had other renal
abnormalities. The 31 survivors were investigated postnatally by ultra-
sound and, where appropriate, by cystogram and ssmTc DTPA scan.
Four babies with fetal hydronephrosis were normal, 2 had non-obstruc-
tive megaureters, 2 had isolated vesicoureteric refiux (VUR), I had a
duplex kidney and ureterocele and 17 had pelviureteric junction (PUJ)
obstruction or tracer hold-up, of whom 3 also had VUR. Seven kidneys
were obstructed on the first DTPA scan, 4 progressed to obstruction
during 3-8 months follow-up, 3 were unchanged and 2 improved during
3-19 months follow-up, and S have not yet been restudied. Fetal renal
pelvic antero-posterior diameter (PD) and renal pelvic/renal antero-
posterior diameter ratio (PD/RD) were measured in 19 kidneys. Nine of
10 kidneys with PD > 10 mm or PD/RI) > 0.5 had significant
abnormalities postnatally (positive predictive value 90%). Four (VUR
2, PUJ tracer hold-up 2) of 9 kidneys with PD 10 mm or PD/RD 0.5
had significant abnormalities (negative predictive value 44%). In con-
clusion, the incidence of antenatally-detected urinary tract abnormali-
ties at Wcstmead Hospital is higher than most reported series, though
the distribution of abnormalities is similar. While elevated values of PD
and PD/RD are predictive of significant pathology, lower values did not
exclude pathology especially VUR.
Treatment of growth retarded children with chronic renal failure with
both strict dietary therapy and recombinant human growth hormone.
Mi. man Renen, Ri. Hogg, J.L. Penfold, A. Sweeney, P.!!. Henning,
K.F. Jureidini, Renal Unit, Adelaide Children's Hospital, Suite/i Aus-
tralia 5006, Australia. Growth failure in chronic renal failure (CRF) is
well established. Previously we have shown that a strict low protein/low
phosphate diet supplemented with keto and amino-forms of the essen-
tial amino acids and histidine. together with energy supplements can
improve growth, while slowing down the rate of deterioration of renal
failure. Nine predialysis boys, aged 4.8—15.7 years with heights less
than the 3rd percentile (%ile) and/or height velocity less than the 50th
%ile for bone age, have been treated with recombinant growth hormone
(Genotropin, Kabi-Pharmacia) tbr eighteen months, in addition to the
above diet. The mean height velocity increased significantly. The mean
height velocity standard deviation score (sos) for chronological age
improved from —1.45 to +3.56 (P c 0.001). Mean height SDS for
chronological age increased from —2.06 to —1.29 (P < 0.001). No
significant deterioration in renal function was observed. Mean glomer-
ular filtration rate (GFR) was unchanged. There was a significant rise in
serum glucose (P C 0.001) and insulin (P C 0.02), although these
remained within the normal range. Mean fasting total cholesterol and
low density lipoproteins fell (P < 0.001) and triglyceride levels rose (P
< 0.01). All other metabolic indices were unchanged. Growth velocity
in children with CRF can be significantly improved, while maintaining
the delay in deterioration of renal function, when treated with a
combination of strict dietary regime and recombinant human growth
hormone. The alterations in lipid profile are of concern.
Peritoneal sclerosis in CAPD. i. Sabto, S.L. Wallace, J. Pedersen,
F.W. Gurr, Alfred Hospital, l'rahran, Victoria, 3181, Australia. Twelve
of 30 patients treated with CAPD developed intractable vomiting,
diarrhea and abdominal pain after 1.5 to 7 years of CAPD. This
complication led to the death of 5 patients and was a factor in the death
of another 5 patients; two patients are alive. Six patients who ceased
CAPD developed tense painful ascites requiring repeated drainage.
Endoseopies and gastrografin studies were not helpful. Plain abdominal
x-rays showed mild upper bowel dilatation and fluid levels. 1.aparotomy
in 6 patients and PM examination in 6 patients revealed one patient had
encapsulating sclerosing peritonitis while 10 patients had peritoneal
sclerosis. Peritoneal sclerosis consisted of a dull, thickened visceral and
parietal peritoneum. The mesentery was shrunken, the omentum con-
tracted, bowel was stiff and peristalsis decreased, Histology showed
mesothelial denudation and peritoncal fibrosis had replaced intestinal
musculature and mesentcric fatty tissue and had encircled myenteric
nervous tissue. At the time of diagnosis no adhesions or pseudomem-
brane were present. The 12 symptomatic patients had been on CAPD
longer than the whole group: mean 59 months (24 to 102) vs. 37 months
(Ito 120); the incidence of peritonitis was the same in the 12 patients
and in the whole group: I episode every 32 patient - month vs. I episode
every 33 patient . months, respectively. Four symptomatic patients
never had peritonitis. Peritoneal sclerosis is responsible for severe
gastrointestinal complications leading to death in a significant number
of long-term CAPD patients.
Placebo-controlled study of blood viscosity and arterio-venous access in
hemodialysis patients following erythropoietin administration. B.i.
Shand, K.L. !.ynn, A.!.. Buttimnure, iA. Inkster, R.R. Bailey, R.A.
Robson, MA. Hurrell, i.E. Wells. Departments of Nephrolagy and
Radiology. Christchurch Hospital and C/mristchurch School qf Medi-
cine. New Zealand. The aim of this study was to determine whether
increased blood viscosity following erythropoietin (EPO) treatment in
hemodialysis patients caused listula thrombosis. Patients (20) were
allocated randomly to receive either EPU 50 U/kg iv or placebo 3 times
a week after dialysis for 3 months. Blood samples were collected before
dialysis. at baseline and at 1, 2 and 3 months. Whole blood viscosity
(37°C) at high (120 s') and low (6 s) shear rates,, plasma viscosity
(25°C) and hematocrit were measured. At the same times recordings
were made during dialysis of fistula arterial diameter and arterial blood
flow velocity (Doppler ultrasound). fistula function (Gambro Fistula
Assessment Monitor [FAM]) and heparin dose. In the EPO group,
significant increases in hematocrit (P <0.001) and high shear rate blood
viscosity (P = 0.006) were found at I. 2 and 3 months. The rise in
hematocrit did not cause significant increases over time in low shear
rate viscosity (P = 0.16) or plasma viscosity (P = 0.14). Neither
hematocrit nor any of the viscosity indices changed significantly in the
placebo group. There were no significant differences in arterial diameter
(P 0.85), ai'terial blood flow velocity (P 0.70) or heparin dose (P
0.80) between the EPO and placebo groups over the 3 months. No
fistula clotted during the study and FAM assessments were the same for
both groups. We conclude that FF0 therapy in hemodialysis patients
results in a significant rise in high shear rate blood viscosity primarily as
a result of increased red blood cell mass. 'l'he rise in blood viscosity.
while being expected to cause increased resistance to blood flow in
large vessels, did not alter fistula function.
Effect of hemofilter (HE) re-use on urea (U) and beta2-mieroglohulin
(fi2m) removal. i. Petrie, Y. Campbell, M. Cobb. P. Hickman, i. Tate,
Renal Unit arid Department of Chemical Pathology, Princess Alexan-
dra Hospital, Brisbane, Q 4102, Australia, Since hemofilters cost
approximately four times as much as conventional dialyzers. cost
effective HF involves re-use. 'l'he performance of dialyzers following
re-use has been evaluated, hut the re-use properties of HF have not
been widely documented. Removal of U and $2in was studied in 16
patients during HF re-use. Blood flow rates, infusion rates and treat-
ment duration were held constant for each patient during the study. 't'he
average number of uses was 4.42 1.8 (range 1 to 7). In 31 studies.
reduction in U concentration was 55.88%! 7.66, 55.30% 8.65, and
54.95 7.68 for the 1st. 2nd and 3rd uses, respectively (NS). In 12
studies, reduction in U was 55.87% 7.9% and 59.22% 10.86% for
the 1st and 5th uses, respectively (paired t-test: t = 1.25. P 0.236.
NS). With regard to ,m removal, there was a considerable difference
between the PAN 250 HF and the Filtral 16. In 52 hemofiltration
treatments with the Filtral 16, the reduction in ,m concentration was
59.11% 12.98%. In IS studies using the PAN 250, it was 2.82%
l0.24%(t 18.7, PC 0.001) Re-use studies on f32m were therfore confined
to the Filtral 16. In 17 studies using the Filtral 16, reduction in ,m was
59.62% 14.53%, 60.11% 12.81%, and 57.60 7.68 for the 1st, 2nd
and 3rd uses, respectively (NS). tn 10 studies the reduction in /32m
concentration was 65.86% 6.53% and 64.89% 7.7% for the 1st and
5th uses, respectively (paired t test, t 0.55, P 0.59, NS). 'I'hus U
and [3,m removal is well maintained for up to five uses of the Filtral 16.
While clearances also appeared adequate on the sixth and seventh uses,
there was insuflicient data to evaluate this statistically.
Hydronephrosis in homozygous Brattleboro rats: A practical guide to
detection. F. Scow, C. Kositz.in, Mi. Field. Departtnent of Medicine,
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University of Sydney, Concord Hospital, NSW 2139, Australia. Hydro-
nephrosis is recognized as an anatomical complication arising in colo-
nies of Brattleboro rats (with hereditary hypothalamic diabetes insipi-
dos), particularly after several generations of inbreeding. Since the
presence of this pathological change invalidates data obtained from
physiological studies using these animals, we sought to develop a
suitable screening test to detect hydronephrosis in intact conscious rats
prior to their use in subsequent micropuncture experiments. Homozy-
gous (di/di) Brattleboro rats, newly bred from American stock, were
placed in individual metabolic cages with free access to food and water.
Daily measurements were taken of body weight (BW), water intake and
urine output. Aliquots of each 24-hr urine sample were analyzed for
osmolality, Na and K. After 2-4 days of observation, animals were
sacrificed (sometimes after being further used in a micropuncture
study), and both kidneys removed for gross anatomical examination.
After coronal section of both kidneys, the degree of hydronephrosis
was graded from absent (grade 0), mild (I) to severe (4), depending on
the extent of loss of medullary tissue. In a number of rats, these visual
impressions were confirmed by making silicone rubber casts of the renal
pelvis. In total, 72 rats were studied, of which 44 were found to be
anatomically normal (N) while 28 had varying degrees of hydronephro-
sis (H). Twenty-four hour excretion of Na and osmoles was not
different between the two groups. However, daily urine volume was
significantly greater in H than N (63.9 1.6 vs. 46.8 1.2 as % of BW,
P < 0.0001) while urine osmolality was correspondingly lower. Using as
a predictive criterion for hydronephrosis a 24 hr urine volume greater
than 55% of BW, 26 of 28 rats with H were detected, while 6 of the 44
N rats were false positives. We conclude that 24-hr urine volume as a %
of BW provides a useful tool, of acceptable sensitivity and specificity,
for noninvasive separation of H from N homozygous Brattleboro rats.
The increased polyuria in rats with H presumably reflects the further
loss of concentrating capacity due to the destruction of medullary
structures.
Assessment of glomerular filtration rate (GFR) in small animals using
intraperitoneal 99mTcDTPA. B.J. Nankivell, R.M. Fawdrv, D.C.H.
Harris, Renal Unit and Department Nuclear Medicine, West,nead
Hospital, NSW, 2145, Australia. The measurement of GFR in experi-
mental animals is limited by current techniques which are inaccurate,
time consuming and may depend on urine collection, intravenous
injection (with risk of extravasation), general anaesthesia or sacrifice. A
simple non-invasive technique for the accurate measurement of GFR in
small animals is described employing a single intraperitoneal injection
of 99mTc DTPA and two timed venous blood samples. Intraperitoneal
99mTc DTPA was rapidly distributed as demonstrated by equilibration
of isotope within 15-30 mm after injection, in rats with bilateral
nephrectomy (N = 5). Plasma time disappearance curves in normal rats(N = 5) followed monoexponential kinetics with stable calculated GFRs
over the interval 30 to 120 minutes after isotope injection. Hence
venous blood sampling times of 45 and 90 minutes after injection were
chosen and GFR calculated by the slope intercept method. Twenty
MBq of 99mTc DTPA produced better than 1% counting precision from
2 accurately measured 50 d samples of plasma. The method was
reproducible with a coefficient of variation in normal rats (N = 6) of 6%
and in stable remnant kidneys (N = 18) of 12%. Correlation to
simultaneously performed inulin clearance was excellent (r = 0.995, N
= 6) over a wide range of renal function. The short half life of 99'Tc of
6 hours allows the technique to be repeated at 1-2 day intervals. The
efficiency of the method (IS rat GFRsI3 hr) and non-invasive nature
make it relevant to ambulatory GFR and suitable for repeated measure-
ments in large numbers of animals. in addition this technique avoids
urine collection, femoral cutdown, sacrifice and the need for constant
infusion or general anaesthesia for injection. In conclusion, the mea-
surement of GFR by intraperitoneal ssmTc DTPA is an easy, rapid,
non-invasive, reproducible and accurate method in small experimental
animals.
Proximal tubular (PT) cell Na transport in compensatory renal hyper-
trophy (CRH). CA. Pollock, M.J. Field, T.E. Bostrom, M. Dyne, A.Z.
Gyory, Dept of Medicine & Electron Microscope Unit, University qf
Sydney, NSW 2006, Australia. PT Na transport and intracellular (IC)
[Nal were assessed in established CRH utilizing combined clearancel
electron microprobe (EMP) experiments in Sprague-Dawley rats. Ani-
mals underwent unilateral nephrectomy (UNx) or sham nephrectomy
(SNx) and were studied 4-6 weeks later. Basolateral Na-K,ATPase
activity was assessed by measuring IC rubidium (Rb) accumulation
following infusion of isotonic RbCI (0.5 rnmol/kg lvi over 30 seconds)
at the conclusion of the clearance studies. IC [Na] and [Rbl were
determined by EMP analysis. To evaluate the contribution of a relative
increase in PT length to the observed changes in PT transport in CRH,
proximal tubules in UNx and SNx animals were filled with silicon
rubber and the lengths of the resultant casts measured. Hyperfiltration
was confirmed in UNx by an increase in inulin clearance to 82% of that
observed in SNx. IC [Rb] was lower in the UNx compared with SNx
(2.08 0.21 vs. 5.02 0.38 mmol/kg wet weight; P <0.001), indicating
decreased Na-K,ATPase activity. If this were the only transport change
occurring, IC [Nal would be expected to rise. However, IC [Na] was
lower in UNx (16.81 0.55 vs. 18.86 0.49 mmol/kg wet weight; P <
0.01), indicating inhibition of Na entry across the apical cell membrane.
Seemingly at variance with this observed inhibition of PT Na transport,
is our previous micropuncture data demonstrating a 48% increase in
total PT Na reabsorption in UNx compared with SNx (2.74 0.19 vs.
1.85 0.31 nmol/min; P < 0.05). However, the current study demon-
strated a 69% increase in PT length in UNx vs. SNx (9.73 0.51 vs.
5.75 0.31 mm; P < 0.0001). These results suggest that increased PT
Na transport in established CRH is med]Lated by an increase in tubular
reabsorptive area. However, Na reabsorption per unit tubular length is
inhibited as the increase in tubular Na reabsorption is only 70% of the
increase in proximal tubular length. We conclude that the most likely
site of inhibition of PT Na reabsorption is the apical membrane.
Glomerular plasminogen activator activity in experimental glomerulo-
nephritis. J. Malliaros. SR. Holdsworth, P.G. Tipping, Monash Uni-
versity Department of Medicine, Prince Henry's Hospital, Melbourne
3004, Australia. Macrophages have been demonstrated to promote
fibrin deposition in glomerulonephritis ((IN) by augmentation of proco-
agulant activity. Alterations in local fibrinolytic pathways may also be
involved in modifying glomerular fibrin deposition in GN. To address
this question, glomerular plasminogen activator activity (GPA) was
measured in supernatants of cultured rabbit glomeruli using a solid
phase plasminogen-dependent 125J fibrin lysis assay. GPA was com-
pared in GN with prominent fibrin deposition (autologous phase anti-
GBM GN) and GN were significant fibrin deposition was not observed
(heterologous phase anti-GBM GN). In autologous phase disease,
injury (proteinuria 899 273 mg/24 hr; normal 15 mg/24 hr) was
associated with macrophage infiltration (79 13 macrophages per
glomerulus [mac/glom]; normal <1 mac/glom) and prominent fibnn
deposition by immunofluorescence. Glomeruli in this disease showed a
significant reduction in GPA (1.27 0.88 ng fibrin lysed per l0
glomeruli in 2 hrs [ngllO3 glom/2 hr], N = 6), compared to normal
glomeruli (57.1 27.8 ng/l03 glom/2 hr, N = 6; P < 0.05). Heterologous
phase disease was associated with marked proteinuria (2188 1408
mg/24 hr) independent of significant glornerular macrophage infiltration
(1.2 0.5 mac/glom) or glomerular fibrin deposition. In this disease
GPA was not down regulated (174 64 ng/l03 glom/2 hr N = 3)
compared to normal. These results demonstrate that in anti-GBM GN
with prominent fibrin deposition and glomerular macrophage infiltra-
tion, local glomerular fibrinolytic activity is markedly decreased or
inhibited. Production of plasminogen activator inhibitors by macro-
phages may contribute to this decreased GPA.
Characterization of membrane bound and soluble human FcyRII in
normal and autoimmune individuals. F. L. lerino, M. Powell, I.F.C.
McKenzie, P.M. Hogarth, Research Centre for Cancer and Transplan-
tation, University of Melbourne, Department of Pathology, Parkville.
Victoria, 3052, Australia. Membrane bound and soluble FcyRII are
implicated in the regulation of immunity especially in the down regula-
tion of B cell function. Furthermore, diminished Fe receptor function
has been demonstrated in autoimmune diseases, including systemic
lupus erythematosis (SLE) and SjOgrens syndrome, resulting in reduc-
tion of clearance of immune complexes and end organ damage. Mono-
clonal antibodies and eDNA cloning techniques have provided a unique
opportunity to systematically investigate soluble FcyRII in normal and
autoimmune disease. A series of monoclonal antibodies (MAbs 8.2, 8.7,
8.26, 7.30) to membrane bound human FcyRII were produced, charac-
terized and subsequently used to measure levels of soluble FcyRII in
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patients with autoimmune disease. The MAbs were compared to
existing human FcyRll MAbs lV.3 and CIKM5 by tissue distribution
using FACS analysis, inhibition of EA rosetting. competitive inhibition
assays between MABs and protein chemistry studies. The relevant
features of these MAbs include: (i) All MAb bind to L-cells transfected
with FcyRII eDNA but not to untransfected L-cells. (ii) These MAb
detect 4 distinct epitopes based on competition experiments and tissue
distribution studies. A radioimmunoassay was developed using MAb
8.26 and 8.7 to detect soluble FcyRll in patient groups. Results show
that patients with autoimmune disorders have significantly higher levels
(mean counts per minute cpm) of soluble FcyRll compared to normals:
normal (N 10) 6,949 834 sr cpm, rheumatoid arthritis (N = 8)
10,580 1151 cpm, (P 0.02) SLE (N = 13), 9,042 595 cpm (P =
0.05) and Sjogren's syndrome (N = 5)12,595 683 (P = 0.001). In
conclusion. (1) this study supports the concept that membrane bound
FcyRIl and soluble FcyRIl are structurally related, as the MAbs
recognize both forms. (2) There is clear alteration in circulating levels of
soluble FcyRlI in autoimmune diseases and may be acting as immuno-
regulatory molecules. To further define the role of FcyRll in autoim-
munity soluble FcyRIl (extracellular domains) was produced from
recombinant cDNA. The expression system is based on methionine
suiphoximine resistance conferred by the glutamine synthetase gene
and expression of the soluble material is driven by a cytomegalovirus
promotor where quantities of recombinant protein >100 mg/liter are
possible.
Polymerase chain reaction in detection of CMV DNA in renal allograft
recipients. W,T. Lee, J. Collins, P. Doak, L. Williams, M.K. Croxson,
K. Powell, H. Antoszewski, Departments of Medicine and Virology,
Auckland Hospital, Auckland, New Zealand. This study utilized poly-
merase chain reaction (PCR) to detect CMV DNA together with viral
cultures and antibody titers to evaluate CMV infection in 24 consecu-
tive patients who underwent renal transplantation with a quadruple
immunosuppression protocol. CMV infection developed in 80% of the
patients with 33% of these patients having organ involvement. A high
incidence of CMV disease with organ involvement occurred in seroneg-
ative recipients of kidneys from seropositive donors (3/6) and in
seropositive recipients of kidneys from seronegative donors (3/7).
OKT3 was associated with a higher incidence of CMV disease with
organ involvement compared with anti-lymphocyte globulin (3/6 vs.
3/17). PCR detected CMV infection earlier than viral cultures or
antibody titers. All patients with CMV-related organ involvement
received a 10 day course of gancyclovir. Patients with a sustained peak
of CMV DNA and patients with a peak of CMV DNA followed by
prolonged low level carriage of CMV DNA were more prone to
recurrence of CMV disease once gancyclovir was stopped. This study
confirmed the high incidence of CMV infection in renal allograft
recipients on an aggressive immunosuppression regimen. Pre-transplant
CMV status remains the best predictor of development of CMV organ
involvement. Earlier diagnosis of CMV infection with PCR and subse-
quent monitoring of CMV DNA levels may provide an opportunity to
target specific antiviral therapy.
Iron accumulation in chronic renal failure. B.J. Nankivell, R.A.
Boadle, D.C.H. Harris, Renal Unit, Department of Medicine & EM
Unit, West,nead Hospital, NSW 2145, Australia. Reactive oxygen
species (ROS) have been implicated in the progression of chronic renal
failure (CRF). As iron catalyzes ROS generation, its presence was
sought in rat remnant kidneys by energy dispersive X-ray microanalysis
(EDXM) and transmission electron microscopy. Striking increases in
Fe containing lysosomes in proximal tubules were noted (7.5 0.4 vs.
0 in control, P < 0.001) when using the Cliff-Lorimer model, which
expresses Fe as a ratio against sulphur intensity. Electron dense
material, confirmed as iron by EDXM was present in 27% of lysosomes,
of which 63% were basolateral. Phosphorus and sulphur were also
present in these lysosomes in increased amounts as were silicon and
zinc, which were associated with Fe. Iron was further analyzed by
EDXM in three models of CRF in rats and quantified by the Hall
continuum method using coembedded Fe-loaded chelex beads as pe-
ripheral standards. Remarkable and consistent accumulation of iron
was demonstrated in lysosomes in proximal tubular cells in each of the
three models, but not in other tubular cells.
P
Models (N = 20)
Remnant kidney
Lysosomal Feb (vs. control)
4.49 0.14 <0.01
Streptozotocin diabetes 3.03 0.08 <0.01
Adriamycin nephrotoxicity 2.69 0.04 <0.01
Control <0.25'
detection limit = 3 x sr of background;' Hall continuum, .t SEM
Preliminary studies in human renal disease show lysosomal Fe present
in a distribution similar to that of the rat. In conclusion, iron accumu-
lates in proximal tubular cells in three models of chronic renal failure in
the rat. Although the origin and significance of this iron is as yet
unclear, it may catalyze the production of ROS, thereby causing
progression of CRF.
Osmoprotectant levels in human and other mammalian kidneys.
P.C.B. Sizeland, ST. Chambers, M. Lever, L. Boson, Departments of
Nephrologv, Infectious Diseases and Biochemistry, Christchurch Hos-
pital. Christchurch, New Zealand. Osmotically-active organic solutes
or "osmoprotectants" have been found in a wide variety of organisms
subjected to a high salt environment. A similar mechanism of adaption
is though to occur in the kidney, particularly the inner medulla, where
these organic solutes would maintain an osmotic balance without
disturbing cellular function. Using high performance liquid chromatog-
raphy we measured the osmoprotectants glycine betaine (GB), myo-
inositol (Ml). sorbitol (S) and glycerylphosphocholine (GPC) in human
and other mammalian renal inner medulla and cortex tissue samples.
Concentrations (imol/g tissue) are shown: (Table, mean SEM)
GB GPC Ml S
Dogs (N 5)
cortex 1.01 0.56 1.43 0.18 3.53 0.92 0.10 0.02
medulla 11.36 1.42 21.14 3.36 16.48 2.56 1.66 0.42
Rabbits (N 5)
cortex 0.37 0.03 1.56 0.25 2.64 0.17 0.07 0.01
medulla 19.52 1.76 18.10 0.58 21.18 1.77 16.06 1.64
Humans (N = 12)
cortex 0.07 0.01 0.94 0.08 2.88 0.18 0.05 0.02
medulla 3.47 0.40 5.08 1.45 14.01 0.97 1.11 0.26
Within a general mammalian pattern there were intra- and interspecies
variations, with the human medulla levels tending to be lower than the
rabbit levels in particular. These compounds are likely to be physiolog-
ically important as osmoprotectants in kidneys. Studies in other mam-
mals can be used as models for the investigation of the osmoprotectant
system in human kidney function.
Placebo-controlled study of blood pressure and vasoactive hormones in
hemodialysis patients on erythropoietin. K.L. Lynn, A .M. Richards,
AL. Buttimore, J.A. Inkster, R.R. Bailey, R.A. Robson, fE. Wells,
Departments of Nephrology and Cardiology, Christchurch Hospital
and Christchurch School ofMedicine, Chri.ctchurch, NewZealand. The
effects of recombinant human erythropoietin (EPO) on blood pressure
(BP) and vasoactive hormones were studied. Twenty home hemodial-
ysis patients received randomly either EPO 50 U/kg or placebo iv.
thrice weekly after dialysis for 12 weeks. No patients were on antihy-
pertensive drugs. BP (Rosebox) and hormones (renin, angiotensin II,
aldosterone and ANP) were measured monthly predialysis. Hemoglo-
bin concentrations rose on EPO (P <0.001) but there were no effects on
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hormones or BP. The BP results were confirmed by weekly measure-
ments made by the patients.
Variable
Systolic BP
Mea
Placebo EPO
Mean
(P — E) P 95% Cl
138 132 5 0.34 —6, 16
Diastolic BP 73 73 0 0.97
—8, 8
Renin nina//liter/hr 2.0 2.5 —0.5 0.47 --2.1, 1.1
Ang 11 pmol/liter 35.6 34.5 I - I 0.75 —7. 9
A!do pmo//liter 846 690 156 0.74 —258, 57!
ANP pmol/ljter 114 85 30 0.07 —9, 68
prestudy value used as covariate
P for main effect. Al! month x treatment interactions, NS
In this group of home hemodialysis patients. EPO therapy over 12
weeks did not affect BP or vasoactive hormones.
Uremic restless legs: Association with anemia and improvement with
recombinant human erythropoietin (rHuEPO). S.D. Roger, D.C.I-I.
Harris, J.H. Stewart, Renal Unit, Department of Medicine, Westmead
Hospital, NSW 2/45, Australia. The pathophysiology of the common
uremic symptom of restless legs is uknown. Therefore. 55 dialysis
patients (34 hemodialysis, 2! CAPD, age 53 7 years. j.i SE) were
evaluated for clinical and laboratory associations of the symptom.
Restless legs was present in 22 (40%) patients, and was associated with
length of time on dialysis (55 10 vs. 25 5 months, P <0.0!), more
severe anemia (Hb 82 4 vs. 95 4 g/liter, P = 0.03) and female sex(P = 0.03) but not with age, clinical features of peripheral neuropathy.
adequacy or mode of dialysis, calcium-phosphate balance, hyperpara-
thyroidism or serum biochemistry. Because of the association of
restless legs with anaemia, the effect of rHuEPO was examined in
another study of 27 hemodialysis patients. The severity of restless legs
(rated by the patient on a 1-7 scale) correlated negatively with hemo-
globin level among all patients (P = 0.03) and those with restless legs
priorto rHuEPO (N = 17, P <0.01). After6 and 12 months ofrHuEPO.
hemoglobin rose from 65 3 to 99 2 and 96 2 g/liter, respectively
in those with restless legs (both P <0.01), and the severity of restless
legs improved from 3.8 0.5 to 5.6 0.4 and 6.0 0.3, respectively
(both P < 0.0!). There was no relation between restless legs and initial
ferritin levels or the need for iron supplements. In dialysis patients the
symptom of restless legs is associated with anemia, and rHuEPO
improves both restless legs and anemia.
Low-dose recombinant human erythropoietin (rHuEPO) reduces costs
in patients on maintenance hemodialysis. D.C.H. Harris, JR. Chapman,
J.H. Stewart, S. Lawrence, S.D. Roger, Renal Unit, Depart,nent of
Medicine, Westmead Hospital, NSW 2145, Australia. Quality of life,
functional capacity and symptoms of hemodialysis patients can be
improved with rHuEPO titrated to achieve a stable hemoglobin be-
tween 90 and 100 g/liter. The costs of rHuEPO were analyzed after one
year of treatment in 24 hospital and satellite hemodialysis patients with
a baseline hemoglobin of 67 2 (c SEM)g/liter. At 12 months, Hb was
93 2 (P < 0,001) and mean rHuEPO dose between 9 and 12 months
only 62 9 U/kg/week LVI. The cost of rHuEPO itself at 12 months was
$A3,681 pa/patient, to which was added the estimated costs of
additional dialyses and medications ($Al,495 pa/patient), bringing the
total to $A5,177 p.a./patient. There was, however, a reduction in
hospitalisation by 8.3 days pa/patient and medical consultation by 3.9
hours p.a./patient. Five patients commenced full-time work and one
took up study aimed at finding work, and 2 patients transferred to home
hemodialysis. Six fewer patients drew social security benefits, and
mean benefits paid fell from $A4,269 772 to $A3,210 852 p.a./
patient. Amongst the IS patients awaiting transplantation mean PRA
fell from 31.0 9.6% to 18.6 6.6% (P < 0.05). The net saving to the
community from using low dose rHuEPO in this group of patients was
more than $1,100 p.a./patient. Low dose rHuEPO not only improves
quality of life and function in hemodialysis patients, but may actually
reduce the costs of renal replacement therapy.
Treatment of uremic hyperlipidemia with simvastatin or MaxEPA.
D.C.H. Harris, L. Simons, E. Hodson, J.H. Stewart, Renal Unit,
Westmead Hospital. NSW 2/45, Lipid Laboratory, St Vincent's Hos-
pital, NSW 2010, Australia. Atheroma, to which hyperlipidemia may
contribute, is an important cause of morbidity and mortality among
patients with chronic renal failure, and yet treatment of hyperlipidemia
remains unsatisfactory. In an open, randomized, parallel group study
the HMG CoA reductase inhibitor, simvastatin, or omega-3 polyunsat-
urated fatty acid MaxEPA, was given for 6 months to 18 moderately
uremic patients (GFR 35 3 mI/mm/rn2, jz + SE; urinary protein 0.92
0.35 g/day). Total cholesterol fell from 8.57 0.49 to 5.51 0.27
mmol/liter (N = 12, P < 0.003) within 4 weeks with only 10 mg
simvastatin and reached a nadir of 4.42 0.26 (P < 0.001) at 4 months
with 40 mg/day. Triglycerides fell from 2.65 0.54 to 1.58 0.20 and
HDL-cholesterol rose from 0.92 0.09 to 1.13 0.10 mmol/liter (P <
0.02). Apolipoprotein (APO) B fell from 1.64 0.09 to 0.82 0.05
g/liter (P < 0.001), while APO A1 did not change. MaxEPA reduced
serum triglycerides (2.89 0.88 to 1.42 0.30), but did not alter other
lipids significantly. Adverse events were common in the simvastatin
group but the majority occurred with a daily dose of 40 mg: a mild
elevation of creatine kinase in 4 patients. myalgia in one patient, and a
rise in serum uric acid in 3 patients who suffered in all 7 episodes of
gout. However, most of these adverse events were mild and self-
limited, so that simvastatin was withdrawn in only one patient. There
were no adverse events among patients treated with MaxEPA. The
hypolipidemic response to simvastatin was rapid, and appeared to be
greater than in non-uremic patients. As most adverse events occurred
with standard doses, dose reduction is recommended in uremia. The
potential benefit of low-dose simvastatin in reducing atheroma needs
examination in patients with chronic renal failure.
Dopaminergic inhibition of aldosterone in normal and hypertensive
pregnancy. MA. Brown, VU. Za,nmit, 0. Mitar, Department of Renal
Medicine, St. Geo,ge Hospital, Sydney, NSW 22/7, Australia. Recent
evidence has highlighted some dissociation between plasma renin
(PRC) and aldosterone concentrations (PAC) during normal pregnancy
and in a number of women with pregnancy-induced hypertension (PIH).
Factors other than angiotensins (e.g. dopamine, ACTH, ANP) may
regulate aldosterone release but have not been studied extensively in
pregnancy. To examine the influence of dopamine upon aldosterone
release in pregnancy, we measured PRC and PAC before and 30
minutes after intravenous metoclopramide, a dopamine antagonist, in
normal pregnant women, women with PtH, non-pregnant women
during both phases of the menstrual cycle and women using the oral
contraceptive pill (OCP). All women were sodium replete and had
similar plasma potassium concentration and 24 hour urinary potassium
excretion before the study. Basal PAC and PRC were significantly
elevated in normal pregnant women compared with either non-pregnant
group. However. PAC increased significantly after metoclopramide in
all groups without a significant change in PRC. Control subjects, who
received 2 ml normal saline only, had no change in either PRC or PAC
over a 30 minute interval, Women with PIH had lower basal PRC and
PAC than normal pregnant women but their percentage increase in PAC
following metoclopramide was significantly greater (P < 0.05). These
findings demonstrate that dopamine exerts an inhibitory effect upon
aldosterone release in both pregnant and non-pregnant women. This
effect is greater in women with PIH and may contribute in part to the
reduced PAC found in some women with this condition. Thus the role
of dopamine in the pathophysiology of NH should be explored further.
Ambulatory blood pressure and albuminuria in normal subjects. R.
Gilbert, T. Allen, P. Phillips, G. Jerums, Departments of Endocrinol-
ogy and Medicine, Austin Hospital, Heidelberg, 3084, Australia. tn-
creased urinary albumin excretion is an important predictor of nephrop-
athy in type t and type II diabetes and of cardiovascular mortality mi
type It diabetes. An elevated albumin excretion rate (AER) is also
associated with benign essential hypertension where a strong correla-
tion between clinic blood pressure and AER has been reported.
Traditionally it is believed that an elevated AER reflects widespread
vascular changes rather than the hydrostatic effect of the prevailing
systemic blood pressure. The aim of the present study was to evaluate
the relationship between AER and blood pressure (BP) throughout the
course of the day. Thirteen normotensise, non-diabetic subjects (8 men,
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5 women) with age 39 9 years (mean so) were studied. No subject
had a history of renal disease, hypertension or cardiac failure. Urine
was collected two hourly during the day in addition to two overnight
collections for a total of 48 hours. BP was recorded half hourly using an
ambulatory sphygmomanometric device (SpaceLabs). BP recordings
during each of the urine collections were averaged and compared with
the AER [radioimmunoassay] and urinary sodium for the corresponding
period. In individual subjects there was a significant relationship (P <
0.05) between AER and mean BP (N = 10).
Subject Mean BP Subject Mean BP Subject Mean BP
I 0.59a 2 061b 3 0.09
4 0.33 5 0.59 6 068b
7 0.66a 8 0.08 9 0.52a
10 0.59 11 059b 12 0.57k'
13 064b
Mean blood pressure vs. log AER [correlation (r), a P < 0.05, b p <
0.01]
We conclude that the observed variability in AER may, in part, be
related to changes in blood pressure. This suggests the possibility of a
direct effect of systemic blood pressure on albuminuria.
Benazepril in chronic renal disease: A double-blind controlled study.
W.M. Van DerMerwe, S. McLigeyo, P.A. Rowe, C. Isles, iD. Briggs,
J. Anderton, Department of Medicine, Middlemore Hospital, Auck-
land, New Zealand and Renal Units, Western Infirmary, Glasgow and
Western General Hospital, Edinburgh, United Kingdom. This study
addressed the specific usefulness of angiotensin converting enzyme
(ACE) inhibitors in the management of renal failure progression, apart
from their systemic blood pressure-lowering effects. We conducted a
double blind, between patient, placebo-controlled comparative study,
using benazepril (Ciba-Geigy), a non-sulphydryl, orally-active long-
acting ACE inhibitor. Participants had chronic renal failure of various
etiologies with demonstrably declining renal function. They were ran-
domized to receive active treatment or placebo in a double blind
fashion. Mean serum creatinine at entry was 347 mol/liter. After a
3-month placebo run-in period, 18 patients in the treatment group
received benazepril 10 mg daily and 19 in the control group received
benazepril placebo for 6 months. Patients were seen monthly. In both
groups, other (non-ACE-inhibitor) antihypertensive drugs were used to
maintain blood pressure control if required, and blood pressure control
was similar. Confirmation of ACE inhibition was obtained by regular
plasma renin estimations. In both groups progression (as measured by
slope 1/creatinine, creatinine clearance and 51Cr-EDTA GFR) was
significantly slowed compared with retrospective data. However, there
was no significant difference between the groups in rates of progression,
proteinuria, renal plasma flow or renal vascular resistance. These
results suggested that low-dose ACE inhibition may not significantly
retard progression of moderate chronic renal impairment, but the
importance of systemic blood pressure control and regular follow-up is
re-emphasized.
Prospective randomized study of the effect of nephrectomy on blood
pressure of patients with unilateral reflux nephropathy. R.R. Bailey,
K.L. Lynn, C.U. McRae, A. Smith. Departments of Nephrology and
Urology, Christchurch Hospital, Christchurch, New Zealand. Hyper-
tension is a frequent late complication of reflux nephropathy (RN). In
the context of unilateral RN the finding of hypertension raises the
question of a surgical cure. A long-term prospective study was designed
to address 2 questions: (1) Could prophylactic nephrectomy of the
damaged kidney prevent hypertension developing in those still nor-
motensive? (2) Would nephrectomy be beneficial to those already
hypertensive? Patients with unilateral RN in which the affected kidney
had a GFR of <10 mI/mm, a normal contralateral kidney and normal
overall renal function were considered for inclusion. The study started
in 1973 and enrolment ceased in 1987. Patients were classified as
hypertensive (>140/90 x 3) or normotensive, and then randomly
allocated to nephrectomy or conservative treatment. The findings are
summarized in the table:
Patient group
No.
patients
Mean [range]
follow-up years
No. on antihyper-
tensive treatment
Normotensive
Conservative 13 [1 lost] 9.1 [3—15] 3
Nephrectomy 9 12.1 [5—17] 1
Hypertensive
Conservative 6 11.5 [8—l71 6
Nephrectorny 6 12.3 [9—161 1
In summary, some normotensive patients with unilateral RN developed
hypertension, but there was no evidence that this could be prevented by
prophylactic nephrectomy. Hypertensive patients benefitted from ne-
phrectomy (Fisher's exact test, P < 0.05).
Renal biopsy findings in Australian Aborigines. M.S. Lloyd, A. Sey-
mour, D.J. Pugsley, Renal Unit, Queen Elizabeth Hospital and Depart-
ment of Histopaihology, Flinders Medical Centre, Adelaide, SA, 5011,
Australia. The prevalence of end-stage renal disease is high among
Australian Aborigines (AA), but the etiology is unclear. Renal disease is
common in diabetic AA, and the finding of unscarred kidneys on
imaging in many other AA with heavy proteinuria suggests that the
prevalence of chronic glomerulonephritis (GN) is also high. A retro-
spective examination was made of 123 consecutive renal biopsies.
These were obtained between 1976 and 1990 from adult AA patients in
South Australia and Northern Territory, Presenting features in the AA
series were classified as follows: Renal failure 45.7% (acute 13.2%),
proteinuria 27%, hematuria 9.8%, proteinuria and hematuria 4.9%,
other 12.3%. The pragmatic, cross sectional nature of such a series
constrains interpretation, but to gain further insights, these biopsies
were compared with a series of 1053 taken from the predominantly
European population of South Australia. (A. Clarkson et al, Proc. 1st
Asian Pacific Cong. of Nephrology, Tokyo 152—157, 1979). A significant
increase in the prevalence of non-IgA mesangiopathic GN (P < 0.01)
and non-hereditary glomerulomegaly (P < 0.001) was present in the AA
series. Diabetic glomerulosclerosis was present in 22% of AA biopsies
(evidence of crescent formation in 25% of these) compared to 2.7% in
the European series. Mesangiocapillary GN was found in 9% of the AA
group compared to 2% in the European series. There were no cases of
membranous GN in AA. Knowledge based on the pattern of renal
disease in the European population is probably not applicable to the AA
population. Similar findings have been reported with respect to the
indigenous populations of the United States, South Africa and New
Zealand.
Analysis of IL-2 mRNA in rejecting renal allografts with the polymer.
ase chain reaction (PCR): A simple method for detection of low-level
message in biopsies. MC. Falk, GA. Bishop, L.P. Roy, J.F. Knight,
Renal Research Laboratories, The Children's Hospital, Camperdown
NSW 2050, Australia. Inflammatory mediators such as the cytokine
IL-2 are believed to be involved in the development and progression of
immunologically mediated damage to the kidney, both in glomerulone-
phritis and in allograft rejection. Analysis of cytokine expression in
tissue biopsies is, however, often difficult because of the small quantity
of tissue available and the low level of expression. We have used
competitive PCR to detect and quantitate lL-2 expression in renal
biopsies, using the method of Gilliland eta! (PNAS 87:2725—2729, 1990).
Genomic DNA and total RNA were extracted by conventional tech-
niques from normal human kidney (obtained from the unaffected pole of
a nephrectomy for tumor), from a biopsy of a rejecting renal allograft
and from peripheral blood mononuclear cells (PBMC) which had been
incubated for 16 hours with phytohemagglutinin. mRNA was converted
to eDNA by reverse transcription. Both the genomic and cDNA
preparations were then subjected to 27 PCR cycles with denaturing,
annealing and extension at 95°C, 55°C and 72°C, respectively, for I
minute each, using oligonucleotide primers specific for IL-2 or /3-actin
and spanning one intron. lL-2 cDNA was detected in stimulated PBMC
and rejecting renal allografts but not in normal renal tissue. f3-actin
cDNA was detected in normal and rejecting renal tissue but not in
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PBMC. Genomic DNA for both genes was detected in all three tissue
samples. Quantitation by competitive inhibition suggested that as few
as 200 molecules of IL-2 could be detected. This method should prove
useful in the analysis of low copy number expression of inflammatory
mediators in immune-mediated renal damage.
A potential role of the tissue renin-angiotensin system in cardiac and
renal disease. B. Jackson, The Department of Medicine, Austin Hospi-
tal, Heidelberg, Victoria, Australia. Angiotensin II stimulates growth
of cardiac and vascular muscle cells in culture, suggesting a potential
contribution by locally generated angiotensin in tissue growth. Studies
of the tissue renin-angiotensin system and the effect of angiotensin
converting enzyme (ACE) inhibition are being undertaken in the rat
heart following myocardial infarction, and in the glomerulus following
nephrotoxic serum nephritis. ACE was quantitated by autoradiograph
densitometry of radioligand binding. In the heart, ACE increased
rapidly over the first 2 weeks (by up to fivefold) in the region of the
infarct, corresponding to areas of acute inflammatory infiltrate. With
the development of ventricular hypertrophy, ACE was increased in
non-infarct areas, by two- to threefold. ACE inhibition from the time of
infarction prevented hypertrophy and was associated with normal
tissue ACE concentration. In nephrotoxic serum nephritis untreated
rats developed mesangial proliferative changes with crescent formation,
hypertension and heavy proteinuria. ACE inhibition reduced both
mesangial change and crescent formation, and reduced proteinuria.
Comparable hypotension with a 3-drug regime did not alter glomerular
injury, nor proteinuria. Variation in tissue ACE concentration may
modulate local angiotensin generation, and contribute to the develop-
ment of cardiac hypertrophy or mesangial proliferation following local
tissue injury.
Is circulating Na-K,ATPase inhibitor in uremia controlled by volume
status? G.S. Stokes, R.J. Caterson, P. Savvas, H-f. Sohn, H.
Johnston, J.C. Monaghan, Hypertension Unit, Departments of Clinical
Pharmacology and Dialvsi.c Service, Royal North Shore Hospital, St.
Leonards, NSW 2065, Australia. This study was designed to show
whether the Na-K,ATPase inhibitor found in uremic plasma by us and
others is involved in volume homeostasis. The effects of volume
contraction (3% body weight in 2 hr) by ultrafiltration (UF) followed by
equivolemic iv. N saline expansion upon plasma Na-K,ATPase inhib-
itor activity, renin activity, aldosterone and atrial natriuretic peptide
(ANP) were investigated in 9 maintenance hemodialysis patients.
Plasma aldosterone increased 2-fold with UF (P < 0.05) and fell to 58%
baseline with saline (P < 0.01). Plasma ANP halved with UF (P < 0.01)
and rose to 166% baseline with saline (P < 0.05). Plasma activities of
Na-K,ATPase inhibitor and renin did not change significantly. Thus,
challenges to volume homeostasis sufficient to induce marked recipro-
cal changes in aldosterone and ANP had no effect on the Na.K-ATPase
inhibitor. In a previous study, it was shown that falls in plasma inhibitor
activity occurred during hemodialysis. The present findings indicate
that these falls were due to dialytic removal of inhibitor rather than
altered blood volume.
Saline infusion into the rat renal artery releases a natriuretic factor.
E.M.A. Bullivant, D.J.B. Muñoz, Department of Physiology, Univer-
sitv of Auckland, Private Bag, Auckland, New Zealand. Infusion of
isotonic saline at low rates (0.05 mI/mm) into one renal artery of
anaesthetized rats caused a prompt increase in sodium excretion by the
infused kidney (from 0.45 0.10 to 2.17 0.40 mol/min/kidney) with
a significant but smaller increase by the uninfused kidney (from 0.21
0.03 to 1.24 0.25 smol/min/kidney). Our experiments tested whether
physical, neural or humoral factors mediated the natriuretic response
by the uninfused kidney. Since there was no significant increase in
sodium excretion with similar infusions of saline into the inferior vena
cava, hemodilution and extracellular volume expansion by the saline
were not natriuretic. In cross-circulation experiments, saline infusion
into the left renal artery of one rat produced an increase in sodium
excretion by the second rat, whereas similar infusions into the infra-
renal aorta did not alter sodium excretion by the uninfused rat.
Isovolemic exchange-transfusion of blood produced an increased so-
dium excretion in the recipient only when the blood came from rats
which received saline infusions into the renal artery. Plasma concen-
trations of aldosterone, angiotensin II (Ang II) and atrial natriuretic
peptide (ANP) were unchanged by renal arterial saline infusion. We
conclude that the natriuresis in the uninfused kidney is not due to
plasma dilution or solely to the action of the renal nerves, but to a
blood-borne natriuretic factor which is not a]ldosterone, Ang II, or
ANP.
Proximal tubular (PT) primary cell culture from normal and diabetic
rats. CA. Pollock, M.J. Field, Department of Medicine, University of
Sydney, Concord Hospital, NSW, 2139, Australia. A technique for
primary culture of rat PT cells on microporous membranes was estab-
lished to facilitate the study of cell growth and epithelial transport. In
each culture preparation, a pure isolate of PT cells is obtained from 6
kidneys by physical separation, collagenase digestion and gradient
centrifugation. Fragments are plated in a concentration of 0.1—0.3 mg
protein/mI on to Millipore filters coated with Cell-Tak. Confluence is
reached at day 5—7, at which time viability of the culture is confirmed by
trypan blue exclusion in >95% of cells. The PT origin of the cells is
confirmed by a doubling of the cAMP production by the tissue at 10
minutes in response to parathyroid hormone, whereas no response was
observed following the addition of arginine vasopressin. Transport
function consistent with PT origin is confirmed by the uptake of alpha
methyl glucose (AMG), which is maximal at 8.4 nmol AMG/mg protein
on day I of culture. Cellular thymidine incorporation is maximal prior to
the cells reaching confluence, after which it remains stable for up to 14
days. Cell cultures from diabetic rats (D cells) are prepared 5—7 days
following the development of steptozotocin-induced diabetes mellitus,
at a time when animals were undergoing glomerular hyperfiltration, and
cellular mechanisms involved in renal hypertrophy had been initiated.
When studied after 24 hours of culture, D cells had a somewhat higher
amount of protein/cell compared to normal cells (16.8 0.6 vs. 14.8
0.9 pg protein/cell; P = 0.06), and, thymidine incorporation was similar
to control (P = 0.42), suggestive of cell hypertrophy in D cells.
Following 24 hours culture, AMG uptake in D cells was increased by up
to 227% of control following 20 minutes incubation (27.6 vs. 8.4 nmol
AMG/mg protein). However, at 7 days this difference was no longer
apparent. We conclude that rat PT cells can be successfully grown in
culture, and that differences in cell growth and glucose transport can be
demonstrated in cells from diabetic animals in the early stages of
culture.
Is vasoactive intestinal peptide (VIP) signilicantly natriuretic in the rat?
MA. Lonergan, M.J. Field, Department of Medicine, University qf
Sydney, Concord Hospital, NSW2139, Australia. It has been proposed
that VIP may play an important role in sodium homeostasis, since in
some species natriuresis has been demonstrated after intrarenal infu-
sion of the peptide. As a prelude to a micropuncture study looking at the
nephron site of this effect, we conducted clearance studies in Sprague-
Dawley rats to determine the overall effect of VIP on the kidney in this
species. Animals were studied under Inactin anaesthesia after overnight
restriction to 8 g of food but free access to water. Ringer's solution was
infused at 1% of body weight/hr following a priming injection of 1%.
After an equilibration period, two baseline clearance periods (20 mm
each) were performed, following which an infusion of VIP in Ringer was
commenced so as to deliver doses of 0.1, 0.4, 0.7 and 1.2 nmol/200 g/hr
(N = 5 rats per group). An additional group of animals (N = 6) received
a continued infusion of Ringer's solution alone, and so acted as a time
control (TC). In all cases, a further 4 clearance collections were made.
Tritiated inulin was included in the infused fluids to permit calculation
of GFR and fractional electrolyte excretion rates. ANOVA was used to
compare results in the various groups. VIP at low infusion rates (0.1 and
0.4 nM) produced a modest increase in fractional excretion of Na
(FEN) of 0.37 and 0.26% respectively, but this was not significantly
different from that seen in the time controls (FENa 0.34%).
Furthermore, in these 3 groups there was a similar small fall in GFR
between baseline and experimental infusion periods. Thus there was
only a minimal increase in absolute Na excretion rates at low doses of
VIP, resembling that occurring in TC animals. At the highest dose of
VIP studied (1.2 nsi), GFR fell significantly more than in the other
groups (LGFR = —1.08 0.13 mI/mm/bOg), and Naexcretionactually
fell, presumably as a compensatory response to renovascular vasocon-
striction. We conclude that when studied by iv. infusion over a wide
dose range in the rat, VIP cannot be shown to have a significant
natriuretic effect.
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Lowering Hb oxygen affinity protects against hypoxic renal injury.
Z.H. Endre, P.J. Rateliffe, P. Stewart-Richardson, D.P. Ferguson,
J.G.G. Ledingham, J. D. Tange, Departments of Medicine, University
of Queens/and and University of Oxftrd, Australia and United Kin g-
dom. Low concentrations of erythrocytes protect the medullary thick
ascending limb (MTAL) against mild and moderate hypoxic injury in
the isolated perfused rat kidney. Proximal tubules (PT) remain sensitive
to perfusate oxygen tension and are the principal target site for hypoxic
injury in this model. To assess whether intrarenal oxygen delivery could
be modulated independently from perfusate oxygen concentration,
isolated rat kidneys were perfused with medium supplemented with
erythrocytes (Uct 2%) with intrinsically low (P50 = 29.3 mm Hg, N 4)
or high (P.rn = 13.3, N 4) oxygen affinity under otherwise identical
conditions (P0, 149 mm Hg = mild hypoxia) and then perfusion fixed
with 2.5% gldtaraldehyde after 180 mm. When perfused with low
affinity Hb, the kidneys had higher initial inulin clearance and lower
FEN, and FEK over the entire 180 mm period. Following perfusion with
low affinity Hb, fewer tubules showed morphological injury than with
high affinity Hb: MTAL (3.3 1.5% vs. 37 14, P < 0.05), SPT (8
5 vs. 33 2, P < 0.005) and in DPT (SI 9 vs. 96 3, P < 0.005).
These results indicate that intrarenal oxygen delivery can be modulated
by manipulating Hb oxygen affinity and that lowering oxygen affinity
can protect against hypoxic renal injury.
Impaired relationship between plasma angiotensin II and its platelet
receptor in insulin-dependent diabetes mellitus. M. Makarios, iA.
Charlesworth, K. Duggan, L.V. Campbell, G.J. Macdonald, Depart-
,nent of Nephrologv, Prince Henry Hospital, Little Bay 2036, and The
Diabetes Centre, St. Vincent's Hospital. Darlinghurst 2010, Sydney,
Australia. There is impaired regulation of the mesangial angiotensin II
(Ang 11) receptor in experimental diabetic nephropathy, and it has been
proposed that this contributes to the disturbance of glomerular hemo-
dynamics that occurs in this disease. This work examined the interac-
tion between plasma Ang 11 and its platelet receptor in patients with
insulin-dependent diabetes mellitus (IDDM). (Previous work has shown
that this receptor is under similar regulatory influences to the tissue Ang
II receptor). The hypothesis was that a comparable receptor abnormal-
ity occurs in human diabetic subjects, particularly in those with clinical
nephropathy. Thirty-nine patients with IDDM (6 with clinical nephrop-
athy) of variable duration were studied with 36 age- and sex-matched
control subjects. Plasma Ang II and its platelet receptor were assayed
by established methods and the receptor number (Bm,,) and dissocia-
tion constant (Kd) examined by the iterative analysis program. LI-
GAND. Plasma Ang 11 concentration was 4.8 0.37 pg/mI in control
subjects with a receptor number of 7.2 1.09 and Kd of 4.98 0.48
E'°. In diabetic subjects, values were 4.3 0.48, 4.3 0.87 and 2.8
0.84, respectively. There was a significant inverse correlation between
plasma Ang II and receptor number in control subjects (log vs.
Ang II; r = 0.38; P < 0.05). This relationship was not observed in
diabetic patients. We conclude that a similar disturbance of the Ang
li/receptor axis occurs in human subjects with IDDM to that observed
in an experimental model of diabetic nephropathy.
Studies to elucidate the genetic abnormality in thin basement mem-
brane disease. J.A. Savige, M. Gallicchio, Repatriation General Hos-
pital, Heidelberg, Victoria 3081, Australia. In thin basement membrane
disease (TBMD), the principal abnormality is an attenuated lamina
densa of the glomerular basement membrane (GBM), but neither the
abnormal protein nor the genetic detect has yet been determined. Since
the lamina densa comprises mainly type IV collagen, we investigated
the possibility of the structural proteins being abnormal in TBMD.
Twenty patients were diagnosed as having TBMD on the basis of mean
GBM thickness being less than 250 am. DNA was extracted from
peripheral blood leucocytes of all 20 individuals. We then examined
eDNA corresponding to the alpha I and 2 chains of type IV collagen and
identified restriction fragment length polymorphisms with Hind 111 and
Taq I, respectively. Examination of DNA with Southern blots demon-
strated neither new alleles nor segregation of the disease with a specific
allele in the 3 families. Renal biopsy material was available from 10
patients and was examined using a monoclonal antibody directed
against the Goodpasture antigen (provided by Jorgen Wieslander). The
Goodpasture antigen was present in the GBM of all 10 individuals. In
addition, we made oligonucleotide primers corresponding to the non-
collagenous domains of the alpha 3 and 4 chains of type IV collagen and
have shown that these genes are present in TBMD. The genetic defect
in TBMD remains to be elucidated.
Insulin-like growth factor-I (IGF-1), insulin-like growth factor binding
protein-3 (IGFBP-3) and growth in children with chronic renal failure.
EM. Hodson, AS. Brown, AR. Rosenberg, Department of Paediat-
,'ic,c, Westtnead Hospital, Westmead, NSW, 2145,' Prince of Wales
Hospital; Prince of Wales Children's Hospital, Australia. It has been
postulated that reduced IGF activity associated with elevated plasma
levels of IGFBP-3 contributes to growth retardation in children with
chronic renal failure (CRF). IGF-l and IGFBP-3 levels were measured
by specific radioimmunoassays in 2 groups of children, aged I—IS years,
with CRF and glomerular filtration rates below 80 ml/min/l.73 m2.
Group I comprised 29 children (lOon dialysis), who were studied 1—4
times over 2 years. As in normal children, IGF-l and IGFBP-3 levels
were significantly correlated, increased with pubertal stage and, in
non-dialysis patients, with age. IGF-l levels, but not IGFBP-3 levels,
increased with age in dialysis patients. Though mean height standard
deviation score (sos) was — 1.26 1.76 5DS in non-dialysis patients and
—2.01 1.76 SD lfl dialysis patients, only 2 values of IGF-l were below
and 6 values of IGFBP-3 were above age-related normal values. There
was no correlation between IGF-l and IGFBP-3 levels (corrected for
age) and height sos. Group 2 comprised 19 children (7 on dialysis) who
were studied prospectively. Mean height velocity 5D5 and mean change
in height sos/year were —1.23 1.48 SD and —0.11 0.29 so/year for
non-dialysis patients and —3.57 1.40 so and —0.38 0.21 so/year for
dialysis patients. IGF-l and IGFBP-3 levels did not differ from age-
related normal values, did not change significantly over I year and did
not correlate with height velocity SDS or with change in height sos/year.
Thus growth retardation in children with CRF is not related to alter-
ations in plasma levels of IGF-I or of IGFBP-3.
Evidence supporting a role for tumor necrosis factor (TNF) in human
glomerulonephritis (GN). H. Macaulay, T.J. Neale, Depart,nent of
Medicine, Wellington School of Medicine, Wellington Hospital, Well-
ington, New Zealand. TNF is a 17 kD peptide cytokine with pleiotropic
inflammatory and immunological functions produced by a variety of cell
types. We have quantitated TNF concentrations in the blood and urine
of patients with a range of biopsy proven ONs using a sensitive ELISA
developed in our laboratory (sensitivity 60 pg/mI) and an immunoradi-
ometric assay (Medgenix, Belgium) (sensitivity 5 pg/mi). The two
assays were shown to correlate and were applied to all specimens in
parallel. Mean serum concentrations of TNF in GN patients (N 34)
did not differ significantly from those of normal controls (N = 12; l4.3
pg/mI 6.9 vs. 10.3 7.7 pg/mI). TNF concentrations were elevated in
the unmanipulated urines of GN patients as a group (N = 57) compared
with normals (N = 20) (16.9 29.4 pg/mI vs. 5.3 3.7 pg/mI).
Non-nephritic patients with other forms of renal disease (N 10) also
had elevated TNF concentrations when compared with normals (15.7
13.3 pg/mi vs. 5.3 3.7 pglml). Certain patient subgroups had elevated
TNF levels: focal glomerulosclerosis (FGS). crescentic GN (CGN), and
membranous GN (MGN). Nephritic patient urines with elevated con-
centrations of TNF demonstrated a 17 kD band when run on 12.5%
SDS-PAGE. confirmed as TNF by immunoblotting with anti-TNF
monoclonal antibody (Boehringer Mannheim). A further ELISA was
developed to measure specific antibodies to TNF in the sera of GN
patients using an heterologous anti-TNF antibody standard curve.
Specificity was confirmed by immunoblotting. Auto-antibodies to TNF
were detectable in II of the 46 sera studied (SLE 3, FGS = 4,
MESPRO = I, CGN = 2, no diagnostic abnormality 1) and in 8 of the
11 cases associated with high levels of TNF in the urine. The genesis
and function of such antibodies are unclear but we speculate that
anti-TNF antibody may act to prolong the half life and action of TNF,
as has been shown in other situations. These studies suggest that TNF
may contribute to glomerular injury in some forms of human GN.
Role of T lymphocytes in experimental glomerulonephritis (GN). M.G.
Lowe, PG. Tipping, SR. Holdsworih, Mona,sh University Department
of Medicine, Prince Henry's Hospital, Melbourne, Victoria 3004,
Australia. The role of humoral mechanisms in the pathogenesis of GN
is well recognized. However, accumulating evidence suggests that
sensitized T lymphocytes within diseased glomeruli may potentially be
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involved in the mediation of injury. To establish a role for T cells as
local effectors of injury in GN, in vivo T cell depletion was performed
in an experimental model of GN. Rats were immunized with sheep
globulin in Freund's complete adjuvant, injected with anti-GBM anti-
body five days later and assessed for renal injury after a further 24
hours. A pan-T cell monoclonal antibody, OX 19, or nonimmune mouse
globulin was administered intraperiteonally, commencing 16 hours prior
to the injection of sheep anti-rat GBM antibody. Glomerular T lympho-
cyte filtration was assessed by indirect immunofluorescence on frozen
tissue sections. Administration of a dose of anti-GBM antibody which
resulted in the binding of 23.7 1.8 jsg kidney-fixing antibody/g kidney
to nonsensitized animals did not cause abnormal proteinuria (15.6 2.3
mg/24 hr; normal, 11.5 1.3 mg/24 hr). Administration of the same dose
of anti-GBM antibody to sensitized rats which were treated with
nonimmune mouse globulin caused significant proteinuria (50.4 11.7
mg/24 hr, P < 0.005). These rats had elevated serum titers of rat
anti-sheep globulin antibodies and significant T cell accumulation within
glomeruli (1.04 0.11 cells/glomerular cross section [c/gcs]; normal,
0.00 0.00c/gcs; P < 0.0005). Treatment of sensitized rats with 0X19
abolished the proteinuria associated with the administration of anti-
GBM antibody (17.6 2.3 ng/24 hr), despite the binding of equivalent
amounts of antibody in the kidney. 0X19 treatment did not effect
circulating anti-sheep globulin antibody titers, but glomerular infiltra-
tion of T lymphocytes was prevented (0.03 0.02 c/gcs, P < 0.001).
These findings demonstrate that abolition of the glomerular influx of
sensitized T cells in this model of GN is associated with the ameliora-
tion of glomerular injury and provide further evidence for a role for
cell-mediated immune mechanisms in GN.
Initial mRNA accumulation in peripheral blood lymphocytes from
human subjects taking cyclosporin A. If. Simpson, R.S. Mead, M.
Skinner, A. Guerson, Department of Medicine, University of Auckland
School of Medicine, Auckland, New Zealand. in vitro studies of
cyclosporin A (CsA) action have established its limitation of the T cell
activation cascade through interference with lymphokine gene tran-
scription and production. Studies of the action of CsA on lymphocytes
in vivo are more limited and have usually examined late events. We
have examined the first dose effect of CsA on lymphocyte mRNA
production in vivo. On three occasions, a normal subject was given
single oral loading doses of CsA 12.5 mg/kg. and the peripheral blood
lymphocyte (PBL) mRNA production for lymphokines and other pro-
teins measured at intervals over a 20 hour period. Precise relative
mRNA quantitation was possible using slot blot analysis. densitometry
and correction for RNA recovery using /3 actin. Whole blood CsA levels
were measured at each time interval. The CsA produced an accumula-
tion of mRNA in the first 2—6 hours, with a later return to control levels.
The effect was most marked with interleukin-2 receptor mRNA (a
36-fold increase) but was also present with y interferon, cs tumor
necrosis factor (10-fold increases) and the MHC class 11 antigen DR/33
(a 6-fold increase). Autologous PBL incubated with CsA containing
serum from the same experiment increased interleukin-2 receptor
expression after 4 hours, suggesting that the mRNA accumulation did
invoke translation. These findings contrast with the in vitro evidence
that CsA acts to stop T cell proliferation by inhibition of lymphokine
gene transcription. The variation in the mRNA increase for a variety of
proteins makes super induction alone an unlikely explanation. The
initial enhancement of mRNA levels for lymphokines may enhance
lymphocyte activation in the first few hours after starting therapy and
could be of importance in clinical transplantation.
Expression of leukocyte adhesion molecules on circulating lymphocytes
in lupus nephritis. V. Timmermans, BA. Pussell, J.,4. Charlesworth,
Department of Nephrology, Prince Henry Hospital, Little Bay 2036,
NSW, Australia. Several groups of cell-surface molecules may promote
adhesion between pro-inflammatory cells and the glomerulus; these
reactions could enhance immunological renal damage. We examined
the expression of one such family of proteins, the integrins. in patients
with lupus nephritis with proven inflammatory cell infiltration. The
hypothesis was that there would be increased expression of those
adhesive molecules with definite intra-renal receptors (such as LFA-l/
ICAM-!) while the C3b receptor (CR1) would be decreased because of
prior occupation by circulating immune complexes. Flow cytometry
was used to study leukocytes in 16 patients and 18 control subjects. The
absolute number of T (CD3+) lymphocytes in patients was reduced
(0.83 0.41 x l09/liter) when compared to controls (1.24 0.33 )<
109/liter; P < 0.01). Expression of the early lymphocyte activation
marker TLiSA- I. the chronic activation marker VLA- I and the leuko-
cyte function associated molecule LFA- 1, was not significantly different
from control values. There was no difference in staining for LFA-l on
monocytes and granulocytes. Expression of the C3b receptor using the
CD35 antibody showed no differences between patients and controls for
lymphocytes or monocytes, but on granulocytes there was increased
expression in patients (1.52 1.6 x l09/Iiter; compared to controls:
0.13 0.19 x l09/liter; P < 0.005). We could not demonstrate any
change in the absolute expression of the adhesive molecules on the
surface of leukocytes in patients compared to control subjects. How-
ever, an unexpected finding was the increased expression of the C3b
receptor on granulocytes. Such enhanced complement receptor expres-
sion may provide additional explanation for the presence of inflamma-
tory cells in the glomerulus.
Detection of anti-myeloperoxidase and anti-elastase antibodies in mi-
croscopic polyarteritis and other connective tissue diseases. J.A. Savige,
M.C. Gallicchjo, J.D. Parkin, Repatriation General Hospital, Heidel-
berg West, Victoria 3081, Australia. Auto-antibodies that produce a
perinuclear pattern on direct immunofluorescence examination on
ethanol-fixed neutrophils (pANCA) arc common in microscopic poly-
arteritis. These antibodies are often directed against myeloperoxidase
or elastase, and we have developed sensitive reproducible ELISAs for
their detection and study. Using sera from patients with microscopic
polyarteritis, both antimyeloperoxidase and anti-elastase antibodies
were demonstrated to be of high affinity. There was no immunoglobulin
class, subclass or light chain restriction noted. Serum titers of both
antibodies fell after treatment with immunosuppressants. Antimyelo-
peroxidase and anti-elastase antibodies were also found occasionally in
antiglomerular basement membrane disease, mixed connective tissue
disease, SLE, post-streptococcal glomerulonephritis and atypical pneu-
monia. These antibodies were not associated with other lung infections
nor recent streptococcal infections other than the cases described
above. Antimyeloperoxidase antibodies were found more frequently
than anti-elastase antibodies, and the, were occasionally present to-
gether. In addition, some sera with pANCA had neither antimyeloper-
oxidase nor anti-elastase antibodies. The target molecules in these
cases remain unclear.
Immunogenetics of IgA nephropathy. P. Hollingsworth, M. Thomas,
H. Moody, R. Dawkins, Departments of Nephrology, Clinical l,nmu-
no/ogy, Royal Perth Hospital, Perth WA 6000, Australia. An immuno-
genetic basis for IgA nephropathy (IgA GN) is suggested by reports of
familial aggregation and founder effects and of associations in some, but
not all studies, of IgA GN with certain alleles of genes in the major
histocompatibility complex (MHC). These include HLA B35, DR4 and
C4A null or C4B null. This study had 3 related goals: I) to reassess
these associations; 2) to demonstrate that such associations could be
explained by increases in certain ancestral haplotypes (AH) of the
MHC, particularly 35.2 and 35.3 which carry B35 and C4B null; 3) to
test the hypothesis that the frequency of AH 8.1 and AH 65.1, which are
increased in IgA deficiency will be decreased in IgA ON, where serum
IgA is commonly high, and never deficient. The study subjects were 36
patients with biopsy-proven lgA GN. and the comparison group were
75 volunteers from the town of Busselton. Both groups were white
European Caucasians, of predominantly British origin. The frequency
of the alleles examined did not differ significantly. However, there was
an increase in B35 (13.9% vs. 6.6%), and in homozygous C4B null
(11.1% vs. 5.4%) as predicted, but not in DR4(20% vs. 34.7%), and not
in homozygous C4A null or heterozygous C4A null or C4B null. AH 8.1
which carries C4A null was significantly decreased, (8.3% vs. 28%, P
0.05), and 65.1 was absent (0% vs. 4.0%) as predicted. AH 7.1 was also
decreased, and AH 18.3, AH 35.1, AH 35.3, Al-I 44.3, AH 57.1 and AH
60.3 were increased (P> 0.05 in every case). We will argue that these
findings imply that the MHC gene(s) relevant to tgA GN is other than
the serologically defined alleles of HLA and C4, and is likely to act via
antigen nonspecific regulation of IgA production.
Effects of sauna on humoral factors in Na handling. H.J. Johnston,
G.S. Stokes, J.C. Monaghan, H-f. Sohn, GA. Crawford, Hyperten-
sion Unit, Department of Clinical Pharmacology and Department of
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Renal Medicine, Royal North Shore Hospital, St. Leonards, NSW
2065, Australia. To stimulate the renin-aldosterone axis by Na deple-
tion, either protracted dietary Na deprivation or a diuretic usually are
employed. We have investigated the use of sauna as a short-term means
of Na depletion and stimulation of this axis. Eight healthy volunteers
(SM, 3F) on a normal diet were exposed to a 25—40 mm period of sauna.
Fluid loss, assessed every 10 mm by body weight and replaced by water
p.o., averaged 0.9% in the men and 0.5% in the women. Plasma renin
activity (PRA) increased from 2.5 0.4 (sEM) to 4.4 0.7 nglml/hr (P
<0.02) and plasma aldosterone from 290 40 to 415 71 pg/mI (P <
0.05). There were no significant changes in plasma atrial natriuretic
peptide (ANP) or ADH concentrations. In 2 male subjects, the proce-
dure was repeated following dietary Na depletion (20 mmol/day) for 6
days. PRA rose with sauna from 4.7 and 7.8 ng/ml/hr to 11.0 and 9.0,
respectively. Plasma aldosterone rose from 613 and 619 pg/mI to 907
and 896. Plasma ANP was suppressed below assay sensitivity through-
out. ADH rose slightly. In a further male subject on normal diet,
sauna-induced Na losses were measured and urinary catecholamines
were determined. Sweat Na loss was 23 mmol during sauna (1% fluid
loss/30 mm). PRA rose from 1.7 to 7.3 ng/ml/hr, and fell to 2.6 ng/ml/hr
40 mm post-sauna. Corresponding plasma aldosterone values were 368,
568 and 526 pg/mI. Urinary adrenaline and noradrenaline showed no
changes throughout. Moderate sauna exposure appears to activate the
renin-aldosterone axis through Na depletion rather than by hypovol-
aemia and neurohumoral stimulation.
Non-collagenous domains of the alpha 3 and 4 chains of type IV collagen
and their relationship to the Goodpasture antigen. iA. Savige, M.
Gallicchio, Repatriation General Hospital, Heidelberg, Victoria 3081,
Australia. The Goodpasture antigen has been controversially localized
to the non-collagenous domain of the alpha 3 chain of type IV collagen.
We performed a number of experiments based on the published
sequences of the putative Goodpasture antigen (M2) and the corre-
sponding sequence of the alpha 4 chain (M3) in order to determine
whether M2 does represent the Goodpasture antigen. First, we demon-
strated by polymerase chain reaction (PCR) amplification that mRNAs
corresponding to M2 and M3 were present in the kidney and that the
published peptide sequences were correct. Second, heterologous anti-
bodies raised against M2 or M3 bound specifically to collagenase-
digested GBM in an ELISA. Third, on Western blots, the anti-M2
antibodies bound to a single high molecular weight band of collagenase-
digested GBM in contrast to the anti-M3 antibodies that bound to the
same bands as Goodpasture serum. Fourth, we demonstrated in ELI-
SAs for antj-M2 and anti-M3 activity that there was no binding of 3 high
titer Goodpasture sera or 2 sera from patients with Alport's syndrome
with inhibitable anti-GBM antibody post-transplant. Thus, while M2
and M3 represent novel type IV collagen chains, the evidence suggests
that M2 does not correspond to the Goodpasture antigen.
Partial purification of a Na,K-ATPase inhibitor from uremic ultrafil-
trate. H-f. Sohn, H. Johnston, R.J. Caterson, G.S. Stokes, Hyperten-
sion Unit, Department of Clinical Pharmacology, and Dialysis Service,
Royal North Shore Hospital, St. Leonards, NSW 2065, Australia. We
have reported the presence of a hemodialysable Na,K-ATPase inhibitor
in the plasma of patients with chronic renal failure. The inhibitor is also
found in ultrafiltrate from such patients, which has been used as a
source of the substance for separation by gel filtration chromatography.
Ultrafiltrate from maintenance hemodialysis patients was lyophilized,
reconstituted in 10 msi ammonium acetate buffer (pH 6.8) and centri-
fuged at 1000 g for 5 mm. The supernatant was loaded onto columns of
Sephadex (G25 and Gb) and eluted with the same buffer at 45 mI/hr.
Protein concentration was monitored spectrophotometrically as absorb-
ance at 280 nm. Elution fractions (5 ml) were collected and assayed for
Na,K-ATPase inhibitor using a linked-enzyme assay. Na concentration
was measured by flame photometry. With G25 Sephadex there were
major absorbance peaks at 2.6 and 3.5 hr. Only the first peak included
Na,K-ATPase inhibitory activity, but it also represented Na co-elution.
With Gb, there were 3 absorbance peaks, at 1.7, 2.0 and 3.1 hr. The
second of these resembled the first G25 peak, but the first GlO peak
included inhibitory activity without Na interference, signifying separa-
tion of partially purified Na,K-ATPase inhibitor. This material was
analyzed by mass spectroscopy.
Sodium lothalamate as an alternative to inuljn in tubular fluid mi-
croanalysis. S.L. Carney, A.H.B. Gillies, C. Ray, Discipline of Medi-
cine, Faculty of Medicine, University of Newcastle, NSW, 2300,
Australia. Micropuncture laboratories can use several different micro-
analytical inulin methods to measure single nephron glomerular filtra-
tion rate (SNGFR) as well as fractional tubular water and electrolyte
transport in experimental animals. A commonly used chemical method
is very time consuming and difficult while tritiated or '4C inulin use is
simple and less time consuming, but labelled inulin is very expensive.
Sodium iothalamate has often been used in clinical and laboratory
measurements of GFR; if infused into experimental animals where
tubular fluid or tissue electrolyte concentrations are measured by
electron microprobe. an iodine peak can readily be detected and used as
a measure of sodium iothalamate concentration. In a series of experi-
ments in Wistar rats, the correlation between tubular fluid to plasma
ultrafiltrate concentration of tritiated inulin and sodium iothalamate was
0.883; P < 0.001 (N = 29). Concentrations of iodine in plasma in the
range of 5 to 10 mmol could be detected. In additional experiments,
GFR with this method was compared with the use of 5tCr EDTA. GFR
measured with iodine was 0.89 0.11 compared to 0.87 0.13
mI/min/l00 g body wt in the 51Cr EDTA group (N = 4). In summary, this
is a simple, economical and accurate alternative to inulin.
Defined minimum-dose subcutaneous erythropoietin (SC EPO) 4000
vs. 2000 unit ampoule. M. Thomas, P. Hurst, G. Thatcher, B. Saker,
Department of Nephrology. Royal Perth Hospital Perth WA 6000,
Australia. Compared to conventional, thrice-weekly EPO therapy of
dialysis anemia using approximately 150 U/kg/wk, major cost-savings
have been generated using a novel regimen of decreasing frequency
4000 unit SC EPO (Lancel 335:1533, 1990) to an individually-defined
minimum dose (DMD4000) capable of maintaining the hemoglobin
concentration (Hb) at 90—100 g/liter. EPO therapy is restricted to
adequately-dialyzed patients with symptomatic anemia, where transfu-
sion is contra-indicated by iron overload, HLA antibody sensitization
or religious objection. Of 20 patients treated, 8 have achieved a
DMD4000, 3 on thrice fortnightly, 3 on weekly, I on 10th daily and I on
fortnightly injections, equivalent to 72 32(35—113) U/kg/week after 13
4 months of therapy. To determine whether this dose could be further
reduced, patients were converted from their DMD4000 to the same total
weekly dose using the 2000 unit ampoule, that is, at twice the fre-
quency. Hb remained constant 8 weeks post-conversion (97 6 vs. 98
8g/Iiter, P = NS) with no change in mean blood pressure (104 8vs.
105 7 mm Hg, P NS) and no complications. In 3 patients to date,
further reductions in 2000 unit dose frequency have been attempted,
producing no change in Hb and a 45% fall in mean dose (88 26 vs. 47
27 U/kg/wk, P = 0.03) and in annual maintenance cost ($A 5268
1140 vs. $A 2911 1362/patient-year, P 0.03j. When given by a
decreasing frequency subcutaneous injection regimen, very low main-
tenance doses and increased cost-effectiveness can be achieved with
the 2000 unit compared to 4000 unit EPO ampoule.
